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Chapter 1. Introduction
Cancer morbidity and mortality in Japan have been increasing. In addition,
less-invasive and higher-QOl (quality of life) treatment for tumors has been in demand
due to the aging of and diversification of values among the population.
There are 3 main methods of treating cancerl surgical, chemical, and radiation
therapies. Surgery is the initial choice for almost all cancers in Japan, as it is an easy
method of extirpating the tumor and allows malignancy grading. Howevet, surgery
necessarily imposes a strain on the patient and can be dangerous for elderly people. It is
also difficult to surgically remove cancer from organs that require functional
preservation, such as the brain or heart. In addition, some patients wish to avoid
surgery for breast cancer or head and neck cancer.
The field of chemotherapy is making rapid progress. Various novel drugs have been
announced and released. In the case of Acute Lymphocytic Leukemia, the outcome of
chemotherapy is often favorable, with a probability of long-term survival of 30% to
500/0lr-61. On the other hand, chemotherapy is not preferred for definitive therapy of solid
tumors. In Japan, it is often used as a supplementary pre- or post-treatment in
combination with surgical or radiation therapy, especially as chemotherapy does not
require knowledge of the exact position of the tumor. Chemotherapy can have a
beneficial effect on residual or tiny metastatic cancers not detectable by CT or MRI. If a
radical curative drug were to be developed, it would become the most widely used
method. Fr.uther development of this field is anticipated.
Like surgery, radiotherapy requires identification of the position of the tumor.
Unlike surgery, radiotherapy is not painful and can be administered as an outpatient
treatment in a similar manner as chemotherapy. In radiotherapy, cancer is irradiated
by an external source (or a small radiation source within the body). This outside energy
has a lethal effect on cancer cells. Forms of external energy therapy other than
radiotherapy include medical ultrasonic and radiofrequency ablation. In external
energy therapy, the energy goes through the normal tissues in front of and behind the
cancer tissue and injures the body parts surrounding the cancer. It is thus important to
reduce the damage to normal cellsi similar concerns apply to chemotherapy. Stereotactic
irradiationtT-el and heavy ion radiotherapytro-rzl were developed to treat deep-seated
tumors by radiotherapy. In stereotactic irradiation, highly focused convergent beams
are delivered so that only the desired target area receives the prescribed dose. A proton
beam or carbon beam is used for heavy ion radiotherapy. Heavy ion beams can generate
a Bragg peak, and this peak can readily be utilized to concentrate the radiation dose on
the tumor volume. However, the damage produced by these therapies is not
insignificant, as normal tissue can receive half of the dose delivered to the cancer
tissuetl3-1s1. Furthermore, cancers near vital organs remain difficult to treat. These
factors lead to cancer recurrence and poor gufg6mss[161.
To resolve this problem, a less invasive treatment was invented using
chemotherapeutic methods. The process consists of injecting a specific drug which
selectively accumulates at the lesion sitei this is followed by local irradiation with an
appropriate energy source. The drug is excited by the external energ'y to produce
reactive oxygen species or radiation, leading to cytotoxicity. Therefore, only the cells
that accumulate the drug are killed. Using appropriately selective drugs, cancers near
vital organs can be treated because the distance is not important. Furthermore,
infiltrative cancer cells near the main tumor mass are treated simultaneously.
Photodynamic therapy (PDT) and boron neutron capture therapy (BNCT) are 2
such therapies, both of which use a quantum beam to excite the drug. Visible light is
used for exciting photosensitizers (light-sensitive substances) in PDt while a neutron
beam is used for exciting the 10B isotope in BNCT. The directness of quantum beam is
higher than that of ultrasound waves or heat, thus enhancing the selectivity.
The selectivity of the drugs and efficient energy transportation are very important
to maximize the benefit of these treatments. I investigated the potential for improving
the efficacy of these therapies by using hemagglutinating virus of Japan envelope(HVJ-E), a novel drug delivery carrier. HVJ-E is a nonviral vector consisting of
inactivated virus particles [17,1s]. HVJ-E can deliver a variety of molecules into cells via
its membrane fusion activity and can be more than 1G-100 times more efficient than
conventional delivery methods. HVJ-E is promising for the following reasonst 1) HVJ-E
is in commercial mass productiontrol, 2) IocaIIy administered IIVJ-E induces
immuno-responses against lumel's[20,2r] and 3) additional selectivity can be obtained by
adding transferrin, cationized gelatin, or monoclonal antibodi sslzz-z+).
In this study, the accumulation of drugs delivered using HVJ-E was examined and
the anti-tumor effect caused by such accumulation determined. After these initial
experiments, I investigated the mechanism by which the reactive oxygen species or
radiation produced by the excited drugs injure the cancer cells, as this knowledge is
important for effective therapy. I found that the cytotoxicity is related to the protein
expression and growth characteristics ofcancer cells.
The second chapter deals with the application of HVJ-E to PDT. Various
photosensitizers have been tested for selectivity with only limited success, especially as
measured by their in uivo therapeutic effectst2s'3l1. HVJ-E was able to increase the
intracellular drug concentration 2O-fold, and the resulting cytotoxicity was also
increased. These results demonstrate the benefits of HVJ-E. The effect of PDT depends
not only on the intracellular drug concentration but also on protein expression. It is well
known that the cells in tumor tissue are heterogeneous[32]. Herein, I isolated 5 types of
cells from a single clone of KYSE7O cells. Some of these isolated cells were significantly
more sensitive than others to PDt irrespective of their intracellular concentrations of
talaporfin sodium (the photosensitizer).
In the third chapter, the potential usefulness of HVJ-E for BNCT was determined
based on the knowledge obtained for HVJ-PDT. An accelerator-based neutron source is
necessary for accessible BNCTlgel. However, various engineering problems currently
prevent the construction of such accelerators[34,35]. In particular, the neutron flux from
existing accelerators is too low to be useful for BNCT. I therefore determined the
possibility of using BNCT with low neutron flux when the boron concentration was
increased by HVJ-E. The first section of this chapter describes the design calculations.
When the boron concentration is increased. 10-fold over that reached by the
conventional method, more than 1 x 106 n/cmzls of thermal neutron flux is required to
deliver the desired radiation dose. It is of course necessary to reduce the fast neutron
contribution as much as possible while maintaining the thermal neutron flux intensity.
The neutron transport was thus estimated using simulation calculations and the shape
and size of the moderator and reflector determined. In the second section, the setup was
built and the neutron flux measured. The strictness of the simulation calculation was
ascertained by comparison with the experimental data. The BNCT effect was also tested
using the setup. Cytotoxicity was confirmed at a dose of 106 n/cm2ls, only a hundredth
part of the amount required for conventional BNCT. Therefore, the increased boron
concentration supported effective BNCT with low neutron flux and reduced the
contributions of fast neutrons and gamma rays. This provides helpful information
towards the development of accelerators for BNCT.
The fourth chapter is devoted to exploring the functional differences of different
radiations using Escherichia coli. It is important to know the biological effects of
radiation when evaluating the effects of radiation exposure or radiation frg2frnsnft36l.
The levels of such effects vary depending on the LET or radiation type, most probably
due to the differences in the radiation damage and subsequent repair processes. The
functional differences between radiations are also important for estimating the effect of
BNCT, as various types of radiation are involved in the BNCT effect: the B (n,o) Li
reaction produces alpha rays, Li rays, and gamma rays. DNA damage and repair
mechanisms are poorly understood. The effect of LET was determined using various
kinds of gene deletion mutants and examining the effects of different growth conditions.
Then a qualitative difference in DNA damage was observed between alpha rays and
gamma rays.
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Chapter 2. The Application of IIVJ-E for PDT and Fundamental Study for
Coverage Expansion
Photodynamic therapy (PDT) is a photochemical modality approved for the treatment of
various cancers and other diseases with neovascularizati6nh,2J. PDT is based on the
interaction of non-ionizing light with a photosensitizing dye. The benefit of light
irradiation is that it is unlikely to be toxic except at thermal doses, limiting the damage
to normal tissue caused by PDT. PDT has a 100-year history. O. Raab used acridine and
halogen lamps to provide treatment for condyloma and female genital neoplasmstsJ.
Hematoporphyrin (HpD) was developed in 1961t41. HpD accumulates in cancer tissue
and initiates a photodynamic reaction, and Dougherty was able to use it to achieve a
complete or partial remission in 1"11 of L13 patientstsl. In Japan in 1989-l-992, Kato
performed fundamental and clinical research on Photofrin and conducted a phase 2trial
for early-stage lung cancer[6]. Based on the results, Photofrin was authorized by the
Ministry of Health and Welfare in 1994 and listed on the National Health Insurance
price list in 1996.
The cancers initially targeted for PDT were superficial esophageal catcinoma,
superficial early-stage stomach cancer, and early cervical cancer, and the outcomes were
favorable. At first, the number of cases in which PDT was used was limited due to the
side effects. Patients had to stay in dark rooms to avoid skin photosensitivity.
Second-generation drugs (Laserphyrin for superficial early-stage lung cancer and
Visudyne for age-related macular degeneration) have recently been authorizedtTl.
However, PDT is still only used for early cancers.
The PDT process consists of injecting a photosensitizer that selectively
accumulates at the lesion sitei this is followed by local illumination of the tumor with a
laser of the wavelength appropriate to activate the specific drug (Figure. 2-1)t81.
Irradiation with light of the proper wavelength leads to the generation of singlet
oxygentel. Activation of the photosensitizer transforms the drug from its ground state
into an excited singlet statei from this state, the drug may decay directly back to the
ground state by emitting fluorescence, a property that can be used clinically for
photodetection. Alternatively, the photosensitizer can undergo electron spin conversion
to its triplet state, the form in which it has a therapeutic photodynamic effect. In the
presence of oxygen, this excited molecule can react directly with its substrate by proton
or electron transfer to form radicals or radical ions that can further interact with
oxygen to produce oxygenated products (a type I reaction). Alternatively, the energy of
the excited photosensitizer can be transferred directly to oxygen to form singlet oxygen
(a type II reactiod, which is the most damaging species generated during PDTtlOl.
To improve the effect of PDI the photosensitizer must be concentrated in order to
maximize its effect on the cancer tissue and the reaction and the reaction in cancer
tissue should be revealed clearly. The first section of this chapter describes my attempts
to increase the photosensitizer concentration using [IVJ-E. The concentration was in
fact improved in .rz uitro experiments, and this change was accompanied by increased
phototoxicity. The second section describes my examination of the relationship between
cell characteristics and the effect of PDT. The cells in a tumor tissue are heterogeneous
in terms of their morphologies and differentiation statuses, even if the tumor consists of
the progeny of a single neoplastic cell. The effect of tumor cell heterogeneity on the
sensitivity to PDT is not known. Here, I demonstrate that a single tumor cell has the
potential to produce heterogeneous progeny. Understanding the effect of tumor cell
heterogeneity on the clinical applications of PDT will aid in the design of new
interventions and potentially improve the long-term survival of PDT-treated patients.
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Figure 2-1. Diagram of photochemical reaction in PDT.
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Section 1. In vitro investigation of efficient photodynamic therapy using a
non-viral vector; hemagglutinating virus of Japan envelope
I.I\ITRODUCTION
Photodynamic therapy (PDT) is a photochemical modality approved for the treatment of
various cancers, skin diseases, and diseases with neovascularizatiol[r,zl. The PDT
process comprises injection of a photosensitizer, which selectively accumulates at the
lesion site, followed by local illumination of the site with a laser of appropriate
wavelength to activate the photosensitizer. Irradiation of the photosensitized area with
light at a specific wavelength leads to singlet oxygen generati6ltal.
The PDT treatment method is associated with minimal injury to patients because
photosensitizers have low cytotoxicity and the excitation light is harmless in the visible
light range. Therefore, PDT is expected to be a less invasive treatment method for early
lung cancers and stomach carcinoma. Moreover, this treatment method also helps
preserve organ function and limits pain compared to existing surgical treatments or
anti-cancer drug therapies. PDT is an ideal treatment for elderly patients, and it may
also improve the patient's quality of life.
Selective accumulation of the photosensitizer in the cancer cells is necessary to
improve the therapeutic efficacy of PDT. However, a limitation of this therapy is the
difficulty in photosensitizers reaching the diseased site, which reduces the efficiency of
PDT therapy. To improve the effectiveness of PDT therapy, a new Drug Delivery
System (DDS) needs to be developed for improving the selectivity of photosensitizers.
The DDS is a technology designed to optimize drug therapy by controlling the drug
disposition and selectively transporting drugs to a target site at a preferred density or
time. The DDS should also effectively reduce side effects and improve the safety of a
given drug.
For the accumulation of drugs in cancer cells, active targeting DDS using
monoclonal antibodies were developed. However, conventional photosensitizers are
mostly hydrophobic, and therefore, conjugation of photosensitizers to antibodies
without compromising the immunoreactivity of the antibodies and thereby in uivo
target accumulation is difficult. Various combinations of conventional photosensitizers
and monoclonal antibodies have been tested to improve their selectivity, albeit with
limited success, especially with regard to in vivotherapeutic efficacyt+-t0l.
Currently, liposomes are used clinically as drug carriers, and polymer micelles,
silica nanoparticles, and carbon nanohorns are potential carriers that have also been
extensively sfufligflttt'rzl. These carriers have also been investigated as photosensitizer
carriers for PDT and have some advantages compared with the administration of the
photosensitizer alonetl3-161. The carriers are composed of 2 defined layers: an outer
envelope and an inner shell. The interaction between the living organism and the outer
envelope of the carrier influences the characteristics of drug disposition, and the inner
shell of the carrier contains the drug. These carriers can be used as active targeting
systems by adding monoclonal antibodies to the outer envelopei the effect of adding
monoclonal antibody was determined in in vivo experimenlsttz-reJ. HVJ'E is a non-viral
DDS carrier having the same bilayer structure and capability as the active targeting
system with antibodytro-zal. In this study, the effectiveness of a new PDT DDS using a
vector based on HVJ-E was examined.
HVJ-E not only encloses drugs and carries them to target sites but also has some
advantages over other carriers. For example, HVJ-E is effective in fusing with other
cellst24l and is therefore expected to improve accumulation of photosensitizers within the
target tumor cells compared with other carriers. Tissue-specific [fVJ envelope vectors
have been constructed (Y. Kaneda, unpublished data, 2005) t25l; this is an additional
advantage of this carrier over other carriers. HVJ-E alone has been shown to have an
10
antitumor effectt26-2s1. In addition, a clinical grade HVJ envelope vector is currently
being produced for use in clinical fuin|stzol Consequently, HVJ-E is a suitable drug
carrier for PDT.
We constructed HVJ-PPIX by adding protoporphyrin IX (PPX) to HVJ-E; PPIX is
being widely used as a carrier in PDT for brain lsp61s[30,err. PDT with PPIX is based on
the endogenous accumulation of PPIX after topical or systemic administration of
5-aminolaevulinic acid (5-ALN t321. The cytotoxicity of PPIX and 5-ALA are low because
they are normal products in healthy tissue. PPIX has absorption peaks at 4O5,510, 545,
580, and 630 nmtas's+I. Vgl'y high absorption was observed at 405 nm, and high
therapeutic effectiveness is expected at this wavelength. Further, the light at a
wavelength of 630 nm is highly transmissible and appropriate for application to deep
lesionsts5l. PPIX is s synthesized inside mitochondria. The amount of PPIX in the cell
depends on the amount of intracellular 5-ALA and the synthesis abilitytaet. For this
reason, there is a limit on the accumulation of PPIX induced 5-AJ,A. HVJ-E can
transport PPIX directly and achieve the high concentration.
The membrane structure of HVJ-E is the same as that of biomembranes, and
hence, small molecules leak out from HVJ-E. Synthetic compounds with their molecular
weight more than 1,000 Da can be incorporated into IfVJ-Et37l. Therefore, encapsulation
of 5-ALA is difficult. 5-AIA must not be added any molecules for increasing the
molecular size because it is required for the synthesis of PPIX for PDT. Therefore, we
constructed. HVJ-PPX from PPIX-C17 (diheptadecanoyl-substituted protoporphyrin IX)
using the PPIX-Cl7t3sl solution technique.
We evaluated the amount of photosensitizer taken up by lung cancer and
melanoma cells rn vitro and the photocytotoxic effect of PDT on the cultured cells by
using HVJ-E with added PPIX. The benefits of using HVJ-E as a DDS for PDT are an
enhanced uptake efficiency of photosensitizer by tumor cells and a selective
photocytotoxic effect because of the cytotoxicity of HVJ-E as well as the PDT.
II. MATERIALS AND METHODS
1. Photosensitizer and light source of PDT
s-ALA (Azzgg, Sigma-Aldrich Inc., USA) and PPIX (Sigma-Aldrich Inc.) were used as
photosensitizers. HVJ-PPIX was generated from PPIX-Cl7. A continuous wave
semiconductor laser generator was used for PDT at a wavelength of 405 nm, at which
the photosensitizers showed a maximum peak of absorption. The cells were grown on a
96-well culture plate (Black with Clear Bottom 96-well MicrotestrM Optiluxtvt Plate, BD
Bioscience Inc., USA), and then irradiated by a Iaser via a fiber attached to the bottom
of the culture plate. An optical instrument with an automated stage for positioning was
purchased from Sigma Koki Co. Ltd., Japan.
2. Vector
The HVJ-E vector is a non-viral vector. The viral activities of the HVJ-E vector were
abrogated by exposure to ultraviolet rays, but the vector still had cell fusion abilities.
DNA, RNA, and proteins can be incorporated into HVJ-E and delivered efficiently both
in vitro and in vivobased on its virus-to-cell fusion ability, which protects the contents
of the IIVJ-E vector from degradation by endosomes and lysosomestzsl. Virus replication
was lost completely, but hemagglutinating activity was not affectedt24l.
3. Synthesis of IIVJ-PPD(
An HVJ suspension of 10,000 HAU was inactivated by W irradiation (gg J/cmz).
Phosphate buffered saline solution (SOO pf,) (PBS, pH 7.4, Sigma-Aldrich Inc.) and
PPX-C17 solution (AZ pf, at a concentration of 11-.5 mg/ml) were added to the 10,000
HAU HVJ-E suspension. After centrifuge separation (fSOOO rpm, 4oC, 5 min), the
supernatant was removed and 200 pL of PBS was added. The PPIX-C17 was prepared
according to the protocol of El-zariat3sl. The incorporation ratio of PPIX in HVJ-E was
2.5 x 10-ts mol per one IIVJ-E vesicle (mean vesicle volume is about 0.11 mmg).
4. Cell culture
The human lung cancer cell line A549 and the murine melanoma cell line 816 were
used. The 4549 cells were cultured in RPMI-1640 medium (Sigma-Aldrich Inc.)
containing L}o/o fetalbovine serum (FBS, Biowest Inc., France), 100 units/ml penicillin,
and 0.1 mg/ml streptomycin (Nacalai Tesque, Japad. The 816 cells were cultured in
Dulbecco's Modified Eagle's Medium (lUnU) (Sigma-Aldrich Inc.) containing 10% FBS,
100 units/ml penicillin, and 0.1 mg/ml streptomycin. The cells were incubated at 37'C
withl% QOz
5. PPD( uptake by cells
For adherent cultures, 100 pL (2 x tO+ cells/well) of the .4549 cells were plated in a
96-well plate. Three hours later, when the cells had adhered to the plate, the medium
was removed and replaced with FBS-free DMEM containing 100 pL of 5-ALA (AOO pM),
PPIX (tOO pM), and HVJ-PPX (100 pM) solution. Conjugation of eight ALA molecules
yields PPIX in a mitochondriai ALA dehydratase synthesizes porphobilinogen (PBG)
from two 5-ALA molecules. PBG deaminase converts four PBG molecules into
hydroxymethylbilane. Linear hydroxymethylbilane is fused into a ring to make
uroporphyrinogen III. Four carboxyl groups are removed to make coproporphyrinogen
ilI. And a coproporphyrinogen oxidase converts coproporphyrinogen III to
protoporphyrinogen Ixt3el. After 2 hours, the supernatant was removed and the cells
were washed once in PBS, lysed with 100 pL of.0.05% sodium dodecyl sulfate solution at
37"C for 30 min, and then the intracellular uptake of PPIX was quantifred using a
multi-mode microplate reader (SpectraMax M5@, Molecular Devices Co. Ltd., USA) with
excitation and emission wavelengths of 405 and 635 nm, respectively.
6. Ffuorescence imaging of intracellular PPD(
4'549 cells were exposed to 5-ALA (SOO plt), PPIX (100 pM), and HVJ-PPX (foo pnn)
dissolved in FCS-free DMEM as described above. After the supernatant was removed
and the cells were washed once in PBS, the distribution of PPIX in the cells was
observed using fluorescent microscopy (gZ-gOOO, KEYENCE, Japan). The excitation
wavelength was 405 Dh, and fluorescence emission was detected at 650 nm.
4',6-Diamidino-2-phenylindole hydrochloride OAPI) (Nacalai Tesque, Japan) was used
to locate the nucleus.
7. Evaluation of the difference of PPD( uptake between cell lines
The amount of drugs delivered using the HVJ-E vector varies depending on the cell line
testedt4ol. We used ,4549 cells and BL6 cells to evaluate the delivery of PPIX via HVJ-E.
The cells were plated into a 96-well plate (2 x 104 cells/well). Three hours later, the
medium was removed and replaced with 100 pL of IIVJ-PPIX suspension (O-ZOO pitt;
dissolved in FBS-free DMEM). After 2 hours, the supernatant was removed, the cells
were washed and lysed, and the intracellular uptake of PPIX was quantified as
described for the PPIX uptake assay.
8. Evaluation of the photocytotoxic activity of PDT
The 816 cells were inoculated into a 96_well Microtestrvr Optiluxru plate (1.25 x L04
cells/well) and incubated for 48 hours. The medium was removed and replaced with L00
pL of 5-ALA solution (O-SO pMi dissolved in FBS-free DMEM) or HVJ-PPIX solution (0-
6.25 pM; dissolved in FBS-free DMEM). After 2 hours, the cells were washed and
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re-suspended in 100 pL of FBS-free DMEM. Cells were then subjected to Iaser
irradiation (50 mwcm2) for 0, 30, 60, or 180 s. After laser irradiation, the culture
medium was replaced with a complete growth medium. After 24 h, the Cell Counting
Reagent SF kit (Nacalai Tesque, Japan), based on a water-soluble tetrazolium
compound, was used to determine the effect of PDT on cell survival. The microplate
reader was used to measure the absorbance at a wavelength of 450 nm. All experiments
were performed in 3 repeats.
9. Statistical analyses
AII data were expressed as the mean + standard derivation. Statistical significance(defined as P values of <0.01) was evaluated using an unpaired Student's /'test
(two-tailed).
III. RESI]LTS
1. Photosensitizer uptake by 
^4'549 cellsThe relationship between the photosensitizer administered and the intracellular
fluorescence intensity is presented in Figure 2-7-1. The amount of PPIX that was taken
up by the cells reached a plateau at2ln (data not shown). Fluorescence intensity with
HVJ-PPX was 3 times higher than that with the PPIX solution and 20 times higher
than that with the 5-ALA solution. Thus, uptake of PPIX was significantly higher with
the HVJ-PPIX solution than with the other solutions.
2. Fluorescence imaging of intracellular PPD(
Figure 2-2-2 shows the results of fluorescence microscopy. PPIX was located
eccentrically in the cytoplasm when the cells were exposed to 5-ALA. However, PPIX
was ubiquitously distributed in the cell when IIVJ-PPX was used.
3. Evaluation of the difference of PPD( uptake between cells
The relationship between the initial concentration of HVJ-PPX in the culture medium
and the fluorescence intensity from intracellular PPIX is shown in Figure 2-1-3. At
HVJ-PPX suspension concentrations of >50 pM, PPIX uptake was higher in the 816
cells than in the ,4'549 cells.
4. Evaluation of the photocytotoxic activity of PDT
The cytotoxic effect of PDT was evaluated in 4'549 and 816 cells. The number of
untreated cells was set at I0Oo/o, and the cell survival rate in the treatment groups was
calculated relative to the untreated cells. Comparing Figures 2-I-4 and2-I-6, or Figures
2-1-5 and 2-7-7, the HVJ-PPIX suspension showed a greater cytotoxicity after PDT than
did the 5-ALA solution.
IV. DISCUSSION
PDT is one of the least invasive cancer therapies, but the accumulation of
photosensitizers in tumor cells is inefficient. One way to overcome this limitation is to
use a tumor-targeted DDS. In our study, we tested the novel DDS vector HVJ-E for the
delivery of photoactive compounds used in PDT. HVJ-E is expected to be a novel DDS
vector. Because HVJ-E is constructed from the inactivated Sendai virus, the
components of HVJ-E are very similar to that of native HVJ. Two glycoproteins, fusion(F) protein and hemagglutinin-neuraminidase (HN) protein, are present on the viral
envelope, and these proteins are important for membrane fusiont2l,4ll. It is likely that
efficient uptake of PDT photosensitinng compounds occurs using this vector through
the fusion of the vector membrane with the tumor cell membrane.
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In the current PDT method, 5-ALA was used. PPIX is formed from 5'ALA in the
mitochondtial{2l. We developed a novel method for the direct transportation of PPIX in
tumor cells using HVJ-E, and showed that HVJ-PPX could be used to inject more
photosensitizers into a cell than 5-ALA. It is unlikely that the improvement in the
injection efficiency of HVJ-PPIX relative to PPIX was only due to differences in the
compounds. HVJ-E increases the injection efficiency by supporting cell adhesion and
membrane fusion using surface proteins. The amount of PPIX induced by IIVJ-PPIX
was 20 times higher than that induced by 5-ALA solution (Fig. 2-1-1), which yields
about 2 to 5 times better results compared with other vectors in earlier studiest€-461.
The distribution of PPIX in the cell was observed using fluorescence microscopy(FiS. z-I-D. ppX was located eccentrically in the cytoplasm when the cells were
exposed to 5-AI"A. 5-ALA is metabolized along a pathway in the mitochondria into PPIX.
Thus Ar,A-PPx is localized in mitochondriat+zl. on the other hand, PPIX was
ubiquitously distributed in the cell by applying HVJ-PPIX. The PDT ability was
maintained. IIVJ-E transfers drugs into cells by cell fusion. The membrane fusion
pathway can spare the endosomal and lysosomal degradationt2sl. Jn our study, It was
considered that PPIX also would take up using the membrane fusion pathway.
In addition, PPlX-induced HVJ-PPX was observed in the nucleus. Because
HVJ-E is often used in gene transfsl[as-s01, it is very likely that HVJ-E allows PPIX to
move into the nucleus by a similar mechanism. PDT results in reactive oxygen species(ROS) and damage to cellular DNA. Thus, the use of HVJ-PPIX has an advantage over
PPIX induced by 5-ALAtzsl.
The amount of PPIX taken up by the 816 and ,4.549 cells was measured (Fig. 3),
and we determined that 816 cells took up significantly about 20-40 percent more PPIX
than .{549 cells. Of course, the growth rate was different between these cells. Although
the uptake of PPIX can affect cell growth, our experiments lasted for only 2 h in
serum-free medium, which eliminated the effect of changes on the cell growth 1a1sl5rl.
HVJ-E binding to the cell surface is mediated by an acetyl-type sialic acid
recognized by the HN protein on the ysgfel[52l. HN-depleted HVJ has low
hemagglutinating activity and the infection activity was supprgsssdts3J. On the other
hand, the transportation by HVJ-E is not affected by inhibitors of endocytosisfzr,zz,s+1.
HVJ-E vector-mediated membrane fusion was also observed by electron
microscopy[21,55],. These results indicate that the PPIX can be directly delivered to the
cytoplasm. Because membrane fusion is needed to the derivation, the receptor of ,{549
and 816 would take an interest in the amount of intracellular PPIX. The membrane
fusion pathway has a higher potential to increase uptake efficiency than does
endocytosis because the endosome aggregates PPIX and decreases the efficiency of
absorption of lighltsG'szl Furthermore the retention time is shortened because PPIX in
coated vesicles is dissolved by the lysosomsstssl.
The photocytotoxicity of HVJ-PPX (Figs. 2-1-6 and 2-L-7) was evaluated in
comparison with that induced by 5-ALA (Figs. 2-L-4 and 2-I-il. High cytotoxicity was
observed both in ,{549 and 816 cell lines. The cytotoxicity for 816 cells (Fig. 2-1-7) was
twice as large as that for 
^4.549 cells (Fig. 2-L-6), which corresponded to the measured
uptake results. The photocytotoxicity of 816 cells was higher than that of .{549 cells
compared in the same intracellular PPIX concentration. Thus, we demonstrated that
the use of HVJ-PPIX resulted in efficient photocytotoxicity considering the amount of
PPIX uptake.
I{VJ-E alone has demonstrated antitumor efficacy without the addition of any
therapeutic agentslzs'ssl. When the concentration of the HVJ-PPX suspension was
greater than 6.25 pM, little cytotoxicity was observed without laser irradiation (Figs.
2-1-6 and 2-L-n. This suggests that HVJ-PPIX retains its antitumor effect. Evaluation
of the photocytotoxic effects of HVJ-PPIX in the tumor-bearing mouse models should
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also be evaluated, along with the in vivo cytotoxicity of the carrier alone. These findings
may be useful for the clinical application of phototherapy in cancer patients.
The in vitro experiments reported in this study did not allow us to evaluate the
tumor selectivity of the HVJ-PPX, but the in uivo selectivity has been demonstrated in
previous researchhe'zsl. The accumulation of photosensitizing compounds in uivo is
critical in the medical application of PDT.
V. SIJMI\{ARY
In this study, HVJ-E was applied to PDT as a novel DDS carrier, and the efficacy of PDT
using HVJ-PPX was evaluated in vitro. As a result, the uptake quantities of the
photosensitizers increased to a greater extent with HVJ-PPIX with previously reported
compounds. Future studies should evaluate the drug kinetics, the amount of
accumulation in the tumor, and the photocytotoxic effect of PDT with HVJ-PPIX using
in uivotumor-bearing animal models..
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Fig. 2-1-1. Experimental setup for laser irradiation of cultured cells on the automated
positioning stage. CeIIs were irradiated with a laser via a fiber attached to the bottom of
the culture plate.
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Figure 2-l'2. The intracellular uptake of photosensitiazer by each cell lines. Graphs
show the fluorescence intensity of intracellular PPIX that was taken up by each cell
lines after 2 h of culture in serum free culture medium.( *P < 0.01-)
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Figure 2-L-3. Intracellular uptake amount of talaporfin sodium A549, 816, CT26 and
LLC cell lines. Fluorescence intensity was expressed against the initial concentration of
HVJ-PPX. The bars indicate cell lines (black barl A549,slashed barl #2, white bari
CT26 and gray bar; LLC). Significant differences (P <0.05) were shown belowi 26
pM:A549 against CT26.50 pM : 4,549 against all other groups 816 against all other
groups. 100 pM : 816 against all other groups. and 200pM:, 4.549 against 816 and LLC,
816 against all other groups.
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Figure 2‐1-4. Antitumor effect of PDT for the A549 cells using 5‐ALA.The cell sur、■val
rate(0/。)is expressed against laser irradiation tilne.The irradiation tilne is indicated as
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Section 2. Direrential erects of photodynamic therapy on morphologlca■y
distinct tumor cens derived ttom a single precllrsor cen
Io lntroduction
Currentl"PDT has been approved for localized diseases and precancerous lesions,such
as bladder cancers,pituitary tumors,and glioblastomasL,刻.Furthermore,numerous
ongoing clinical studies have been designed to optilnize the conditions of PD■and
thereafter PDT has been approved in several countries. HoweveL one inherent
consequence of PDT is local hypottia,which can arise directly froln oxygen consumption
during treatlnenti3‐』Or ind士ectly from the destruction of the tumor vasculature as a
result of effect市e treatment膝,」.Hypoxia is a maior stimulus for angiogenesis,through
its stabilization ofthe hypoxia‐inducible factor‐lα(HIF10 transcription factOr膊],which
results in an increase in the production and secretion of vascular endothelial growth
factor GrEGDD].Followmg PD■an increase in VEGF secretionhO,1■and angl genic
responses have been documented ゴb ヮゴИメ12,1』。vEGF induction could cont五bute to
tumor sl】rvlval and regrowth,and therefore could be one of the factors impairing PDT
from achieving its full tumoricidal potential. Therefore, a better understanding of
responses by tumor cells following PDT will help design new interventions and
potentially improve the long‐ternl sl rvival of PDT treated patients.
It is well known that the cells in a tumor tissue are hёterogeneousin terms oftheir
morphologies and differentiation statuses,even ifthe tumor tissue consists of a progeny
that is derived fron■a single neoplastic celll141.Although cultured tumor cells have alsO
been characterized by their morphologlcal heterogeneity the extent of cellular
morphological heterogeneity cannot be easily evaluatedo When Shilnada et al.assessed
the survival of 31 cultured human esophageal tumor cells using a colony‐forlning
assayL司,they found that one cell group(KYSE 70)formed multiple morphologically
distinct colonies in a single dish.Classification of the colonies made it possible to
evaluate the extent of the morphological heterogeneity.Here,I isolated five types of
cells from a single clone of KYSE70 cells.The sensit市ity of some of t se i olated cells
to PDT was significantly higher than that of others,irrespect市e of theむintracellular
concentration of talaporfin sodium(the photosensitize→.In addition,the vEGF
production by each cell type was different after PDT Based on these results,I propose
that a small fraction of tolerant cells may actively grow and predominate after PD■
even though most ofthe non‐tolerant cells in the o五ginal tumor tissue were selectiヤly
killed by the repeated treatment in clinical therapy.
IIo Mate五ls and lnethods
lo Materials
Talaporfin sodium Ovlono‐1‐aspartyl chlorin e6,Laserphyrin①,kindly provlded by 1/1eiii
Seika Co.Ltd.,Japan),composed of aspartic acid cottugated by lneans of an amide bond
to the]D ring of the chlorin structure,with an absorption peak at 664 nn■as used as
the photosensitizer. A continuOus wave selniconductor laser generator was used,
wavelength;664±l nm(」ENOPTIK unique‐mode GmbH,Germanyp.¶.e cells on a
culture plate were irradiated by the laser宙a a rlber attached to the bottom of the
cultllre plate. An optical instrument with an automated stage for positioning was
purchased frolln Sigma Koki Co.Ltd.,Japan.
2。Cen cult1lre and isolation
The KYSE70 cells were cultured at 37°C and 5%C02 in Dulbecco'sM[odified Eagle's
Medium(DMEM)(Sigma‐Aldrich lnc。,MO)containing lo%fetal calf serum(FCS,
BioWest lnc.,France),100 units/mL penicinin,and o.l mg/mL streptomycin(Nacalai
Tesque,Japan).ShilnOda et al.previously described the origins and other details of this
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cell type and established the KYSE70 cells from a poorly differentiated human
squamous cell carcinoma (from an esophageal cancer that had developed in a
77‐year‐old Japanese male)L5,ld.A KYSE70 cell suspension (10 cells/mD was
inoculated into eath well of a 96‐well p ate(10011L/well,Corning lnc。,NYy,and the cells
were incubated for 3 days.Under microscopic observation,only a single morphological
formation 6f cells in each well was selected and cultured continuously.The cell number
of each cell type was sequentially counted to calculate the cell growth rate.
3.GrOwth speed
For stationary culture, 100 11L of each selected morphological cell subclone was
inoculated into 96‐well(625 cells/welD.24,48,72,96, 120 hours later,the cells were
counted by MTT assay.The Cell Counting Reagent SF kit(Nacalai Tesquめ,based On a
water‐soluble tetrazolium compound,was used for the counting assay.
4.Setermination of the cen size
The suspettding solution(1×106 cellS/m⊃was made and cell diameter was measured by
Coulter counter llnethod using flow cyto五eter(Cell Lab Quanta sc h[PL,Beckman
Coulter lnc。)。
5。Anticallcer drug reslstance
For stationary culture, 100 11L of each selected morphological cell subclone was
inoculated into 96‐well(5×103 cellS/well).Twenty‐four hours latet when the cells had
adhered to the plate,the lnedium was removed and the cultures were washed three
times in a phosphate buffered saline solution(PBS,pH 7.4,SigmD.Then,100 11L of
5‐Fluorouracil(5‐FU,Sigma‐Aldrich lnc.was added to each well(62.5,125,250,500 or
100011g/m⊃dissolved in FCS free DⅣIEM)。A t r 48 h,the cells were counted by MTT
assay.
6.Talaporfm sodium uptake by cens
For stationary cultllre, 100 11L of each selected morphological cell subclone was
inoculated into a Black with Clear Botto五96‐ ell■〔icrotestTM OptiluxTM Plate(BD
Bioscience lrlc.,CD (1×104 cellS/welD.Twenty‐four hours later,when the cells had
adhered to the plate,the mediun■was r moved and thё cultures were washed three
times in a phosphate buffered saline solution(PBS,pH 7.4,Sigmめ.Then,100 11L of
talaporfin sodium was added to each well(10,30,or 50 11g/mL;dissolved in FCS free
DMEM).After 2 h,the supernatant was removed and the cells were washed three times
thorOughly with PBS,lysed with 100 11L of O.05%sodium dodecyl sulfate solution at
37°C for 20 1nin,and the intracellular uptake oftalaporfin sodium was quantified using
a multi‐mode microplate reader(SpectraMax M5①,Molecular De宙ses Co.Ltd.,CD
with excitation and elnission wavelength of 405 and 672 nn■,respectively.Then the cells
were counted by fluorometric quantitation of cell DNA with Hoechst 33342 solution
(Nacalai Tesque, 」apaD according to the assay protocol[17].The fluore,cence
interference between the intercalated Hoechst 33342 and the talaporfin sodium was
separated using an optical filter instrument. A calibration curve between the
concentration of DNA and the number of cells was made using cell suspensions with
different known cell concentrations.All experilnents were performed seven independent
tillnes.
7.Amollnt of generated ROS
The way oftalaporfin sodium uptake was described above.The lnedium was replaced to
FCS free DLIEⅣl added Fluorescent detector of highly ROS IAn■inophenyl f uorescei ,
APDo Cells were then subieCted to laserむrad ation(30 mW/cm2)fOr O,30,60,or 180 s.
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After PDT, the fluorescence of APF (405 nm) was measured.
8. Evaluation of the antitumor activity of PDT using talaporfin sodium and a
semiconductor laser
Each selected morphological cell subclone was inoculated and exposed to talaporfin
sodium dissolved in FCS free DMEM (10, 30, or 50 pg/ml) as described for the
talaporfin sodium uptake assay. Cells in FCS free DMEM were then subjected to laser
irradiation (30 mWcm2) for 0, 5, 10, 30, 60, or 180 s. After laser irradiation, the culture
medium was replaced with complete growth medium. After 24 h, the number of cells
was counted to evaluate their sensitivity to PDT using MTT assay. The SpectraMax Mb
was used to measure the absorbance at a wavelength of 450 nm. All experiments were
done three independent times. The results of these counts were independently verified
using a DNAbased counting method.
Colony assay was also used to counting cell number. The cells after PDT were
retrieved and inoculated into a 6-well plate (costarG) 3595, Corning Inc.) (fOO cells/well
or 1000 cells/well). They were cultured for Tdays using DMEM containing 1.2%
methylcellulose (R&D Systems, Inc.) and the number of colony was counted.
Chronological change of cell survival rate was also measured. Cells were counted 3,
6, 12 or 24h after PDT using MTT assay.
To determine the rate of talaporfin sodium photobleaching, a photobleaching test
was performed using a talaporfin sodium solution. The talaporfin sodium was
photobleached based on the formula: C = Co exp(-kt), where C is the concentration at
time (t), C0 is the initial concentration of talaporfin sodium, and k is the coefficient of
photobleaching. The value of k was determined experimentally to be 0.0024, when the
initial concentration of talaporfin sodium was 10, 30, or 50 pg/ml. From this result, we
estimated that 90% of talaporfin sodium remained in the cells after a 60 s laser
irradiation.
9. Area under the curve GUC) calculations
To clarify the relationships between phototoxicity (PDT effects), laser irradiation time,
and the intracellular uptake of talaporfrn sodium, the area under the phototoxicity-
laser irradiation time curve GUC) was calculated using the linear trapezoidal method
and the correlation between the AUC and the intracellular concentration of talaporfin
sodium was evaluated.
10. ELISAs
Each selected morphological cell subclone was inoculated, exposed talaporfin sodium
dissolved in FCS free DMEM (10, 30, or 50 pg/ml), and laser irradiated as described
above. TWenty-four hours later, the VEGF level in the cell culture medium was
quantified from each sample using a Quantikine human VEGF ELISA kit G&D
Systems, Minneapolis, MN).
11. Statistical analyses
All data were expressed as means + the standard derivation. Statistical significance(defined as P values <0.01) was evaluated using an unpaired Student's t-test(two-taile0.
III. Results
1. Appearance of morphologically variable cells
Cells with varying morphologies were observed in a well, in which a single KYSE7O cell
had been inoculated (Figure 2-2-7). These cells were classified into five types (subclones
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#7-5): Subclones #-J", #3, and #4 were flat and diffusive cells, and subclones #2 and #5
consisted of cell mounds.
The cell growth rate was different for each subclone, but there were no
correlations between cell morphology and growth rate (Figure 2-2-2). The cell diameter
was measured by Coulter counter method (lable 2-2-D. Each subclone is significant
difference from all other subclones. The biggest is #4 and the smallest is #5. And the
sensitivity to anti-cancer drug was shown in Figure 2-2-3. Subclone #3, #4 had have
great sensitivity.
2. Photosensitizer uptake by cells
The relationship between the initiai concentration of talaporfin sodium in the culture
medium and its intracellular uptake is shown in Figure 2-2-4. The amount of talaporfin
sodium that was taken up by the cells reached a plateau at 2 h (data not shown).
Irrespective of the concentration of talaporfin sodium in the medium, the cells from
subclone #3 took up much talaporfin sodium. However, there was no correlation
between the amount of intracellular talaporfin sodium uptake and cell morphology.
When observed under fluorescence microscopy, the cytoplasm was the major site for
talaporfin sodium uptake, with little talaporfin sodium in the nuclei of any of the ceII
subclones (data not shown).
To ensure that the lack of serum did not affect the uptake of talaporfin sodium, I
measured the intracellular uptake by each cell subclone in culture medium containing
10% serum. Under these conditions, the uptake of talaporfin sodium was slightly lower
compared with the uptake in serum free culture medium. However, these differences
were not significant.
3. Amount of generated ROS
The amount of ROS generated by PDT was measured using APF fluorescence. The
fluorescence intensity was expressed against the laser irradiation time in Figure 2-2-5.
Subclone #I, #2 and. #4 generate more ROS than #3 and #5 regardless of talaporfin
sodium
4. Evaluation of the antitumor activity and VEGF secretion after PDT using talaporfin
sodium and a semiconductor laser
The cytocidal effects of PDT were evaluated for each cell subclone. When the
concentration of talaporfin sodium was 30 or 50 pg/ml, the phototoxicity of PDT was
proportional to the length of laser irradiation (Figure 2-2-6). However, irrespective of
talaporfin sodium concentration, the phototoxicity in subclones#2 and #5 was markedly
lower than in the other clones 3 h after PDT. Additionally, when the concentration of
talaporfin sodium was 10 ;:.glmL, there was no obvious effect of PDT on any of the
subclones. Figure 2-2-7 is a result of antitumor activity measured by colony assay. The
antitumor effect was measured larger compared with MTT assay.
The correlations between the areas under the phototoxicity-laser irradiation time
curves (AUC, calculated from Fig. 2-2-il and the amounts of intracellular talaporfin
sodium uptake $iS. 2-2-D are shown in Figure 2'2-8. These data revealed that under
these conditions, subclones #3 and #4were more resistant to PDT than subclones #I,#2
and #5, irrespective of the amount of intracellular talaporfin sodium or the laser
irradiation time.
The amount of VEGF released into the cell culture medium was quantified 24 h
after PDT for each subclone (Figure 2-2-il. Since PDT decreased the number of cells for
subclones #1 and #2, t};.e concentrations of VEGF in the culture media was also
decreased when 30 or 50 pg/ml of talaporfin sodium was added. However, their VEGF
concentrations were increased after PDT when the talaporfin sodium concentration was
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10 pg/ml. In contrast, VEGF production was not detected in culture media of subclones
#&-5 before or after PDT.
fV. Discussion
Morphological heterogeneity is frequently observed in cells cultured in vitrotls-ls1. In
general, these alterations are induced by intracellular and/or microenvironmental
alterations and are considered to be reversible. Shimoda et al. found that a single
cultured human tumor cell (KYSE70) formed multiple types of colonies in a culture
dishtlsl. I classified these cells into 5 groups according to their morphologies (Fig. 2-2-l),
which did not change over the course of our experiments.
I compared the gxowth speeds (fig. z-z-z), cell diameters (Table 2-2-l), and
resistances to anti-tumor drugs (nig. Z-Z-S) among the 5 groups and found that subclone
#3 grew the most rapidly but was less sensitive to drugs than was subclone #4 and more
sensitive than were subclones #7, #2, and #5. Although highly proliferative cells are
generally more drug-sensitive, subclone #5 was the most drug-sensitive despite a
growth rate similar to those of subclones #I, #2, and #4. These results show that the
proliferation potential of the 5 subclones was not related to the 5-FU sensitivity. There
have been some reports of a drug-efflux pump effective against 5-FU, and some of the
subclones may express this pumptlel.
From the morphologically variable appearances of the cells, it might be expected
that differences in cell surface area would influence the intracellular concentrations of
talaporfin sodium, as the ceII surface area can contribute to the uptake of this &rg,.
However, there was no correlation between the apparent cell surface areas and the
intracellular talaporfin sodium levels, suggesting that the cell populations, although
derived from a single cell, have markedly heterogeneous intrinsic talaporfin sodium
uptake properties. While the growth rates differed among these cell subclones and may
have affected the uptake of talaporfin sodium, my experiments only lasted 2 h in
serum-free medium, allowing us to ignore any growth-related changes in uptake.
In PDT the presence of a drug-efflux pump would reduce the drug amount. In my
experiments, therefore, the presence of a drug-efflux pump should be related to the PDT
effect. The survival rates for the subclones after PDT were measured by the MTT assay
and the values found to differ Gig.2-2-7). The cell proliferation and the times between
cell damage and death after PDT were also different. The cytotoxicity estimated by
colony assay was higher than indicated by the MTT assay, possibly because cells may
not die until a few days after the damage occurs[27,28]. In my experiments, the cells
continued to die over 24 h after PDT.
To clarify the correlation between the effects of PDT (phototoxicity vs. laser
irradiation time) and the intracellular talaporfin sodium concentrations, I analyzed the
relationship between AUC (calculated from a graph plotting phototoxicity against laser
irradiation time) and the intracellular concentration of talaporfin sodium (Fig. 2-2-D.
The results indicated that cell subclones #L.#2 and #5 were more sensitive to PDT than
were cell subclones #3 and #4, despite having lower levels of intracellular talaporfin
sodium. Therefore, although cell subclones #3 and #4 took up larger amounts of
talaporfin sodium, this uptake did not boost the effects of PDT. A number of studies
have examined the effectiveness of photosensitizers on multidrug resistant cellswith a
focus on the effects of the P-glycoprotein (P-gp) or the ATP binding cassette GBC)
transporter on the efficacy of PDTtzo'zal. Some multidrug-resistant ABC transporters
might be expressed in KYSE7O cellsi the possibilities include MDR1/P-gp/ABCB1(multidrug resistance gene 1lP-glycoprotein/ATP-binding cassette family B1),
MRPI/ABCCI (multidrug resistance-associated protein/ATP-binding cassette family
C1), and BCRP/ABCG2 (breast cancer resistance protein/ATP-binding cassette family
G2). Therefore, due to the potential influence of drug efflux pumps on intracellular
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talaporfin sodium levels and consequently on PDT in this study I measured the
amounts of intracellular talaporfin sodium just before laser irradiation.
Numerous studies have reported biological changes in cells in response to PDI
such as decreased cell adhesion[2e,30] and increased production of cytokinest3ll and levels
of heat shock proteinstszl. Those studies also described the effects of subcurative PDT
and reported increased VEGF production both ra vitro and in vivo.In this study, only 2
of the 5 subclones expressed VEGF (Vie. Z-Z-g), and VEGF expression was decreased
after PDT (in proportion to the decrease in cell number) in those subclones. However,
VEGF production was increased when the PDT effect was not sufficient to decrease the
number of cells (10 Ug/mL talaporfin sodium). The details of the clinical relevance of the
induction of VEGF by PDT are currently under investigation, but VEGF could
contribute to tumor survival and regrowth and could therefore be one of the factors
preventing PDT from achieving its full tumoricidal potential. Abetter understanding of
the responses to PDT and VEGF secretion capacities of morphologically heterogeneous
tumor cells could significantly improve therapeutic outcomes.
Morphologically heterogeneous cells have been observed frequently not only in
primary lqsleyslt+J but also in metastatict33l and recurrent fumelstsal after tumor
therapy, although it remains unknown whether such morphological alterations are
reversible. Ttrmor recurrence is a serious problem for patients because recurrent tumors
are frequently more malignant than primary tumorstesl. Furthermore, it is well known
that recurrent tumors are usually more resistant to further chemo- or radiotherapy. TWo
hypotheses might explain this resistance. First, treated cells become committed to
de-differentiation and thus acquire tolerance. Second, a large fraction of the
non-tolerant cells in the original tumor tissue are selectively killed by repeated
treatments, leaving only a small number of more tolerant cells to grow actively and
become predominant. My data show that cell subclones #I, #2, and #5 were more
PDT-sensitive than were subclones #3 and #4. If the subclone #3 and #4 cells more
actively migrate to other tissues, it could explain why PDT has been slow to gain
acceptance as an alternative to conventional tumor therapies. Therefore, a better
understanding of the influence of tumor cell heterogeneity on the clinical applications of
PDT will aid in the design of new interventions and potentially improve the long-term
survival of PDTttreated patients. Further improvements in the clinical applications of
PDT for heterogeneous tumor cells can be expected, and improved PDT may ultimately
be useful as a clinical antitumor therapy.
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Figures
Table 2-2-7 T}:e cell diameter in each subclones. Each subclone is significant difference
from all other subclones.
cell subclone Cell diameter ( + SD) [um]
13.8 ( + 3.S)L3.2 ( + a.4)
r5.4 ( + a.3)17.2 (* a.7)
r2.5 ( * 3.5)
Table 2-2-2. Differential reactions on morphologically distinct tumor cells derived from
a single precursor cell for talaporfin sodium Phortodynamic Therapy. Typical results
are expressed. The bold face numbers indicate higher impacts or quantity than the
other subclones.
#1    #2    #3    #4    #5
Growth rate in five days 14 19 45 L4 77
Intracellular concentration of
talaporfin sodium [mg/cell] 1.10 1.30 1.90 L.70 0.81
(dose concentration = 50 mg/ml)
Emergence amounts of ROS
measured by APF intensity [a.ul o.
/a\ctose concentratlon = bu mg/ml,
Irradiatioin time = 180 s )
Survival rate of control after PDT
(dose concentration = 50 mg/ml, 0.06 0.08 0.30 0.15 O.2I
Irradiatioin time = 180 s )
Amount of VEGF after PDT (dose
concentration = L0 mg/ml, 257 84 0 2.6 9.7
Irradiatioin time = 180 s )
?
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Figure 2-2-L Morphologically variation. Morphologically variable cells were observed.
(A) Onty a single morphological formation of ceils in one well were selected and cultured
continuously. (g-F) Five subclones were separated from a single clone of KYSE70 cells.
Bar = 200 um.
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Days in culture ldayl
Figure 2-2-2. The ceII gowth rates of subclones #t-5. The cell growth rate was different
for each subclone and there was no comelation between the morphology of a cell and its
growthrate. The symbols indicate cell subclones (O; #L,l;#2, L;#3, V;#4. x;#il.
100 200 300 400
5-FU ooncentration lpelml]
Figure 2-2-3. Antitumor effect of 5-FU in each subclone. The cell survival rate was
expressed against the concentration of 5-FU. Cell subclone # is indicated as O; #1,8;
#2, L; #3, V; #4. x i #5. *Significant differences were shown belowi 62.5 pglmL:
subclone #1- against #3, 4, subclone #2 against #3, 4, 5, subclone #3 against #L, 2, 5,
subclone #4 against #1, 2, 5, subclone #5 against #2, 3, 4. t25 pg/ml : subclone #1
against #3, 4, 5, subclone #2 against #4, 5, subclone #3 against #I, 4, 5, subclone #4
against all other groups, subclone #5 against all other groups. 250 trtglmL: subclone #1
against all other groups, subclone #2 against #L, 4,5, subclone #3 against #L, 4, 5,
subclone #4 against all other groups, subclone #5 against all other groups, 500 pglml, :
subclone #1 against #4, 5, subclone #2 against #4, 5, subclone #3 against #4, 5, subclone
#4 against all other groups, subclone #5 against all other groups.
500
﹇??」?????」????」??﹈??????」???????
,'tt ?M-x 'x. ---..
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0 '10 30 50
Concentration of talaporfin sodium lpelml]
Figure 2-2-4.Intracellular uptake amount of talaporfin sodium into each cell subclone.
Intracellular amount of talaporfin sodium was expressed against the initial
concentration of talaporfin sodium in the culture medium. The bars indicate cell
subclones (black bari #l,slashed bari #2, gray barl #3, white ba$ #4. dotted barl
#5).*Significant differences were shown belowi 10 pg/ml,: subclone #1 against #2, 4,5,
subclone #2 against #I, 4, 5, subclone #3 against #5, subclone #4 against #1, 2, 5,
subclone #5 against all other groups. 30 pg/ml : subclone #1 against #4, subclone #2
against #4, subclone #4 against#L, 2,5, subclone #5 against #4. 50 pg/ml : subclone #2
against #5, subclone #3 against #5, subclone#  against #5, subclone #5 against#z, 3, 4.
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Figure 2‐2‐5.Fluorescence intensity of APF was expressed against the laser irradiation
tillne when the initial concentration of talaporfin sodium in the culture medium was
ω 10,(B)30,and(C)50 μg/mL.Cell subclone is indicated as O;#1,□;#2,△;#3,▽;#4.
×;#5.
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Figure 2-2-6. Chronological change of cell survival rate. The cell survival rate was
expressed against the laser irradiation time when cell subclone is (A)subclone #1 and(g)*2, and subscript expressed the initial concentration of talaporfin sodium in the
culture medium as (t)tO, (z)go, and, (3)50 pg/ml.. Elapsed time is indicated as O; 3 h,
!; 6 h, L;I2}r', V;24 h. The initial concentration of talaporfin sodium in the culture
medium was 50 pglml,. (continued)
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Figure 2-2'6. Chronological change of cell survival rate. The cell survival rate was
expressed against the laser irradiation time when cell subclone is (C)subclone #3 and(D)+a and subscript expressed the initial concentration of talaporfin sodium in the
culture medium as (t)t0, (z)gO, and, (3)50 pglml,.. Elapsed time is indicated as O; 3 h,
tr ; 6 h, L;12 h, V; 24 h. The initial concentration of talaporfin sodium in the culture
medium was 50 pg/ml. (continued)
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Figure 2-2-6. Chronological change of cell strrvival rate. The cell survival rate was
expressed against the laser irradiation time when cell subclone is (A)subclone #1, (B)#2,
(C)+9, @)*4, and (E)#5 and subscript expressed the initial concentration of talaporfin
sodium in the culture medium as (1)10, (z)gO, and, (3)50 pg/ml.. Elapsed time is
indicated as O; 3 h, n; 6}n, L;Lz h, V; 24h.T}re initial concentration of talaporfin
sodium in the culture medium was 50 pg/ml.
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Figure 2‐2-7.Antitumor e]lect of PDT using talaporfin sodium measllred by colony
fornling assay. The number of colony formation was expressed against the laser
irradiation tilne when the initial concentration of talaporfin sodiuln in the culture
medium was lAn10,(B)30,and,(C)50 μg/mL.Cell subclone is indicated as O;#1,□;#2,
△;#3, アヽ;#4. ×;#5.
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Figure 2-2'9. Amount of VEGF after PDT using talaporfin sodium. Amount of VEGF
was expressed against the irradiation time when the initial dose concentration of
talaporfin sodium in the culture medium wasi 10(A), 30(B), and 50(C) pg/ml. Cell
subclone is indicated as O;#1.tr;#2. A; #3. V;#4. x;#5.
﹇???????﹈?」????」????ぅ???
﹇???????﹈
」?﹈??」????っ???
﹇???????﹈?」????」????ぅ???
40
2.
3.
4.
References
1. SB, Brown EA, Walker I. The present and future role of photodynamic therapy in
cancer treatment. Lancet Oncol. 2004, 5@)t 497-508
Dougherty TJ. An update on photodynamic therapy applications. J Clin Laser Med
Surg. 2002,20(1):3-7
Sitnik TM, Hampton JA, Henderson BW. Reduction of tumour oxygenation during
and after photodynamic therapy in vivo: effects of fluence rate. Br J Cancer. 1998,
77(9):1386-1394
Henderson BW, Busch TM, Vaughan LA, Frawley NR Babich D, Sosa TA, Zollo JD,
Dee AS, Cooper Mt Bellnier DA, Greco WR, Oseroff AR. Photofrin photodynamic
therapy can significantly deplete or preserve oxygenation in human basal cell
carcinomas during treatment, depending on fluence rate. Cancer Res. 2000,
60(.3):525'529
Chen Q, Huang Z, Clnen H, Shapiro H, Beckers J, Hetzel FW. Improvement of
tumor response by manipulation of tumor oxygenation during photodynamic
therapy. Photochem Photobiol. 2002, 7 6(2) : 197 - 2O3
Engbrecht BW, Menon C, Kachur AV, Hahn SM, Fraker DL. Photofrin-mediated
photodynamic therapy induces vascular occlusion and apoptosis in a human
sarcoma xenograft model. Cancer Res. 1999, 59(JD:4334-4342
Fingar VH, Kik PK, Haydon PS, Cerrito PB, Tseng M, Abang E, Wieman TJ.
Analysis of acute vascular damage after photodynamic therapy using
benzoporphyrin derivative (BPD). Br J Cancer. 1999, 79ftI-I2):17O2'L78
Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol. 20OI,
r3e):t67-L7t
Forsythe JA, Jiang BH, Iyer NV, Agani $ Leung SW, Koos RD, Semenza GL.
Activation of vascular endothelial growth factor gene transcription by
hypoxia-inducible factor 1. Mol Cell Biol. 1996, 6(9):4604-4613
Deininger MH, Weinschenk I Morgalla MH, Meyermann R, Schluesener HJ.
Release of regulators of angiogenesis following Hypocrellin-A and -B photodynamic
therapy of human brain tumor cells. Biochem Biophys Res Commun. 2002,
298(4):520-530
Ferrario A, von fiehl KE, Rucker N, Schwarz MA, Gill PS, Gomer CJ.
Antiangiogenic treatment enhances photodynamic therapy responsiveness in a
mouse mammary carcinoma. Cancer Res. 2000, 60(15):4066-4069
Jiang F, Zlnang ZG, Katakowski M, Robin AM, Faber M, Zhang E, Chopp M.
Angiogenesis induced by photodynamic therapy in normal rat brains. Photochem
Photobiol. 2oo4, 7 9(6): 49 4- 498
Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A,
Naumann GO. Influence of photod5mamic therapy on expression of vascular
endothelial growth factor (VEGF), VEGF receptor 3, and pigment
epithelium-derived factor. Invest Ophthalmol Vis Sci. 2003,44(lO):++ZS-++gO
Nowell PC. The clonal evolution of tumor cell populations. Science. 1976,
L94@260)123-28
Shimada Y, Imamura M, Wagata I Yamaguchi N, Tobe T. Characterization of 2l
newly established esophageal cancer cell lines. Cancer. !992 Jan I5;69e):277-284
Shimada Y, Maeda M, Watanabe G, Yamasaki S, Komoto I, Kaganoi J, Kan I
Hashimoto Y, Imoto I,InazawaJ, Imamura M. Cell culture in esophageal squamous
cell carcinoma and the association with molecular markers. Clin Cancer Res. 2003,
g(.r):z+s-z+g
Rao J, Otto WR. Fluorimetric DNA assay for cell growth estimation. Anal Biochem.
L992,207(]-):186-792
Bai J, Nakamura H, Ueda S, Kwon YW, Tanaka T Ban S, Yodoi J.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
41
22.
23.
19.
20.
21.
24.
25.
26。
28.
29.
30.
Proteasome‐dep ndent degradation of cyclin Dl in l‐IInethyl‐4‐phenylpyr dinium
ion O嘔PP十)‐induced cell cyde arrest.J Biol Chem.2004,279(37):38710‐38714   ヽ
Yuan J,Lv H,Peng B,Wang C,YuヽHe Z.Role of BCRP as a biomarker for
predicting resistance to 5‐且uorouracil in breast cancer. Cancer Chemother
Pharmacol.2009,63(0:1103‐1110
Capella MA,Capella LS.A light in multidrug resistance:photodynamic treatlnent
of multidrug‐resistant tumors.J Biomed Sci.2003,10(0:361‐366
Merlin」L,Gautier H,Bttberi‐Heyo  M,Teiten MH,Guillemin R The multidrug
resistattce modulator SDZ‐PSC 833 potentiates the photodynamic act市ity ofchlorin
e6 independently of P‐glycoprotein in multidrug resistant human breast
adenocarcinolna Cells.Int J Oncol.2003,22(の:733‐739
Lil吼Zhang W」,Ohnishi K,Yamada I,Ohno R,Hashimoto K.5‐Aminolaevul nic
acid‐mediated photodynamic thёrapy in multidrug resistant leukemia cells.J
Photocheln Photobiol B.2001,60(2‐3):79‐86
Teiten ⅣlH,Bezdetnaya L,LIerlin JL,Bour‐Dill C,Pauly LIE,Dicato Ⅳl,Guillelnin
E Effect 6f meta‐tetra(hvdroxyphenyl)chlorin(mTHPC)‐mediated photodynamic
therapy on sensitive attd multidrug‐resistant human breast cancer cells. J
PhotochellII Photobiol B.2001,62(3):146‐152
Zhou S,ZongヽNey PA,Nair G,Stewart Ctt Sorrentino BR Increased expression of
the Abcg2 transporter du五g e ythroid matllration plays a role in decreasing
cellular protoporphyrin IX levels.Blood.2005,105(6):2571‐2576
Robey 雨 、Steadman K, Polgar O, Bates SE.ABCG2‐mediated transport of
photosonsitizers: potential impact on photodynallnic therapy. Cancer Biol Ther.
2005,4(2):187‐194
Limoli CL,Hartmann A,Shephard L,Yang CR,Boothman DA,Barthololnew」
,
MOFgan WE Apoptosis, reproduct市e failure, and oxidative stress in Chinese
hamster ovary cells with comprolnised genomic integrity. Cancer Res。 1998,
58(16):3712‐8
Lock RB, Stribinskiene L.Dual modes of death induced by etoposide in human
epithelial tulnor cells a1low Bcl‐2 to inhibit apoptosis without affecting clonogenic
survival.Cancer Res.1996,56(17):4006‐4012
Runnels J1/1, Chen N, Ortel B, Kato D, Hasan ■ BPD‐MA‐media ed
photosensitization in vitro and in 宙vo: cellular adhesion and betal integrin
expression in ova五an cancer cells.Br J Cancer。1999,80(7):946‐953
Rousset N,Vonarx v Eleouet S,Carre J,Kerninon E,Laiat x Patrice T Effects of
photodynattic therapy on adhesion molecules and metastasis. J Photochem
Photobiol B。1999,52(lT3):65‐7
Dougherty TJ, LIarcus SL. Photodynanlic therapy. Eur J Cancer. 1992,
28A(10:1734‐42
Luna MC, Ferrario A, Wong S, Fisher ANI, Gomer CJ.Photodynamic
therapy‐mediated oxidative stress as a molecular sⅥntch for the temporal
expression of genes ligated to the human heat shock promotero Cancer Res.2000,
60(6):1637…1644
Fidler IJ,Hart IR.Biological d市ers ty in metastatic neoplasms:origins and
implications.Science.1982,217(4564):998‐003
Beyer DC. Brachytherapy for recurrent prostate cancer after radiation therapy.
Semin Radiat Oncol.2003,13(2):158‐165
Ⅵ■eeler」A,Zagars GK,対ala AG.Dedifferentiation of locally recurrent prostate
cancer after radiation therapy. Evidence for tumor progressiono Cancer. 1993,
71(11):3783‐7
27.
31.
32.
33.
34.
42
Chapter 3.Ttre Applicability of IfVJ-E to Accelerator-based BNCT and the
Development of a Setup for in vivo and in vitro Studies
The second chapter indicated that HVJ-E is capable of being useful for low-molecular
weight drug delivery. HVJ-PDT was highly effective at achieving therapeutic drug
concentrations. I therefore applied HVJ-E to Boron Neutron Capture Therapy (BNCT).
In theory, BNCT provides a way to selectively destroy malignant cells while
sparing normal cells. It is based on the nuclear capture and fission reactions between
boron-1O (toB) and thermal neutrons. toB is a nonradioactive constituent of natural
elemental boron. The reaction cross section is exceptionally large, i.e., -3800 b at
thermal neutron energ"y. 1oB thus captures thermal neutrons very efficiently and
produces energetic cr particles (+He) and recoiling lithium-7 (zli) nuclei via a toB (n,
o)-zli reaction (Figure 3-1). These particles have high reactive biological effectiveness(RBE) and a range of less than 10 pm in tissuetll. Because the high linear energy
transfer (LED particles have limited path lengths in tissue, the destructive effects of
these high-energy particles are limited to boron-containing cells. The dose to normal
tissue is limited by the drug specificity and control of the irradiated area. An affected
site near a vital organ can be cured by BNCT because the physical distance has little to
do with the side effects. As boron is accumulated selectively, as in chemotherapy, BNCT
has curative properties against small infiltrating cancers. It also decreases the risk of
recurrence.
The theory of BNCT was advanced by Locher in 1936t21. Clinical trials of BNCT
were started in 1951 at Brookhaven National Laboratory by Sweellal and Javid, Javid et
a].tal, snd Farr et al.t5l. However, the trials were discontinued after the treatment of 17
glioblastoma cases at the Massachusetts Institute of Technology in l-960-l-961 due to
the discouraging clinical results. Interest in BNCT was renewed by Hatanaka in Japan,
who had worked at Massachusetts General Hospital with the BNCT team headed by
Sweet. Hatanaka modified the procedure developed by Sweet at MGH in 1960-1961 by
introducing 10B-sodium-mercaptoundecahydrododecaborate (toB-NazBrzH-SH).
Between 1968 and 1992, l2O patients with 119 intracranial tumors and 1 extracranial
nerve-related tumor were treated by the current standard BNCT technique. The clinical
results for Grade 3-4 glioma patients treated before March 1985 were reported in
comparison with those for control patientstel. Japan is therefore in a position to build on
this success and lead this field. To date. clinical studies on BNCT for head and neck
cancer have been conducted using the Kyoto University Reactor or Japan Research
Reactor No. 4. However, BNCT is now receiving attention around the world, and clinical
studies have begun in Italy and Argentina. The implementation status of BNCT at
home and overseas is described in Table 3-l- and Table 3-2.
Neutron sources for BNCT are currently limited to nuclear reactors, which is one
of the biggest reasons for the limited understanding and slow spread of this technique.
1.0 x 10e n cm-2's-r thermal neutrons are needed for BNCT using current standard
protocols, and only reactors can achieve this rate. There is no reactor specialized for
BNCT. Research reactors present obstacles to treatment, with insufficient medical
settings and legal restrictions. Furthermore, reactots are generally installed in
suburban areas, and it is difficult to build them adjoining hospitals. The construction
and operational costs are also very high.
To overcome these difficulties and make BNCT a useful modality for the treatment
ofcancer, accelerator-based BNCT has been suggested. Accelerators can also be used to
produce neutrons, and accelerator-based neutron sources are being developed in several
countries t7-131. These sources are also compact enough to be sited in hospitals, thereby
allowing more effective but technically more complicated BNCT procedures to be carried
out. However, to date, various engineering problems have precluded accelerator-based
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therapy. Developing effective accelerator-based BNCT is thus important for both
experimental study and therapy.
The dose of BNCT is provided mainly via the toB (n, o)-zli reaction. The absorbed
dose is thus proportional to the product of thermal neutron fluence and 108
concentration. Therefore, if the drug concentration can be increased, the accelerator
load can be decreased substantially. High accumulation and selective delivery of boron
compounds into tumor tissue and cancer cells are therefore most important for
achieving effective BNCT while keeping the concentration as low as possible in adjacent
healthy cells.
Some novel drugs have already been reported to accumulate to levels 10-20 times
higher than those of ordinary drugs. For example, Suzuki et al. reported the efficacy of
administering a lipiodol emulsion of sodium mercaptoundecahydro-closo-dodecaborate
(BSH), producing a boron concentration in liver tumors of 197.3 [pp-]ttnl. Kahl et al.
reported that in tumor-bearing rats receiving boronoporphyrins (BOPP) by
convection-enhanced delivery (CED), CED of 1.5 mg BOPP produced an average tumor
boron level of 519 [ppm]ttsJ.
The 2 most promising boron compounds to emerge from investigations of hundreds
of low-molecular-weight boron-containing chemicals were
[(L)- -dihydroxy-borylphenylalaninel, based on arylboronic acids and called Bp4tral, and
another compound based on a newly discovered polyhedral borane anion called BSHI171.
The mechanism of accumulation is not clear but is related to the amino acid transport
system. Various amino acid transporter activities are enhanced in rapidly multiplying
cells, and L-amino acid transporter-l (I"AT1) imports BPA into cells and may play a
major role in the efficacy of BPA-based BNCT. BSH is a small, lipophilic compound with
a cage-like structure and is the boron carrier most commonly used for BNCT for
glioblastoma. Clinical experiengslral and the results of studies dedicated to the
investigation of BSH pharmacokinetics and boron biodistributiontle-2zl encouraged the
European collaboration on BNCT to proceed toward clinical use of BNCT. While BSH is
unable to pass the intact blood-brain-barrier (BBB), it has been to selectively penetrate
the BBB at tumor sites because of damage to the BBB by the infiltrating malignant
cellst23l. BSH consists of l-2 108 atoms and has been under investigation for the
treatment of glioblastoma.
A boron concentration of 
-20 pg/g can be achieved in tumor tissue. This value is
too low for treatment with accelerator-based neutron sources. Therefore, the boron
concentration must be increased using Drug Delivery System (DDS) technology. If the
108 concentration could be centuplicated, even a small, weak neutron source that
generates a hundredth part of the thermal neutrons produced by a nuclear reactor
would be effective. In the present study, fundamental BNCT experiments were
conducted with a combination of the Intense 14 MeV Neutron Source Facility,
OKTAVIAN, of Osaka University and novel boron agents (HVJ'E and B-Liposomes),
which are anticipated to further progress in boron localization. The OKTAVIAN facility
generates 14 MeV neutrons via the Deuterium-Tlritium (D-T) reaction. The generated
neutrons must be moderated to the thermal range for use in BNCT.
In the first section, I confirmed the feasibility of formulating a setup for verifying
the logic described above. The neutron transportation rates, fluxes, and spectra were
calculated using simulation calculations using Monte Carlo N-Particle Tlransport Code:
MCNP5l24l. The size of the sample area was decided first, and then the rough geometry
was designed. The materials for the reflector and modulator were selected and the
optimal size was calculated by comparing the neutron fluxes.
In the following section, the anti-tumor effects of accelerator-based BNCT were
determined in uivo and. in uitro using the setup built in the first section. The
intracellular boron concentration and the cytotoxicity of the novel agent were measured
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after the experimental conditions were set.
Finally, I will discuss t}ne in vivo expertments. The BNCT effect was not detected
in the in uitro experiments described in the second section, which is suspected to be due
to the affinity of HVJ-E for the LLC cell line. Therefore, a cell line meeting the
requirements for measuring the BNCT effect was chosen and the setup was improved
by the use of deuterium water.
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Table 3-1. Implementation status in Japan as of 2009
Reactor Organization Brain Skin Other TotalTerm
HTR
」RR‐3
L[uITR
KUR
KUR‐ⅣI
」RR-2
」RR‐4
Hitachi, Ltd.
Japan Atomic Energy Agency
Musashi Institute of Technology
Kyoto University Research
Reactor Institute
Kyoto University Research
Reactor Institute
Japan Atomic Energy Agency
Japan Atomic Energy Agency
?
?
?
?
??
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
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?
?
?
13
1
108
61
1968…1974
1969
1977-1989
1974,87,90-95
1996-2006
1990-1996
1999‐2007
105
0
35
Total 352 33 140   525
Table 3-2 Implementation status of the world as of 2008
Country Reactor Range Cases Region Term
United States of
America
Netherlands
Finland
Sweden
Italia
Argentina
Research
research
thermal
epithermal
thermal
epithermal
epithermal
epithermal
epithermal
epithermal
epithermal
epithermal
brain
brain
brain
brain
brain
skin
brain
brain
brain
brain
liver
melanoma
1951～58
1959～61
1994～99
1959～61
1994～
1997～
1999～
2000～
2001-05
2002～
2003～
Brookhaven's Graphite rr- 
-_____ -r
. tnermalIiesearc.n lteactor 28
17
54
18
24
22
150
2
52
2
7
Brookhaven Medical
Research Reactor
MIT Nuclear Research
Reactor
The High Flux Reactor(HFD Petten
Finland
Reactor
Czech Republic  LVR‐15
R2-0
Research Reactor
Research Reactor
thermal:En<0.5 eV epithermal:0.5 eV<En<10 keV
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Section 1. Development of thermal neutron freld with D-T neutron source aiming
at in vitro experiment for BNCT
I. Introduction
Recently the number of cancer cases has been increasing. In addition because of aging of
the population and diversification of values among the people, less-invasive and
high-QOL (quality of life) treatment for tumors has been required. Boron Neutron
Capture Therapy (BNCT) is known to be a less-invasive tumor therapy based on a
reaction between boron (toB) and thermal neutron. r0B captures a thermal neuwon very
efficiently (in an exceptionaly high probability) and produces energetic a and zl,i
particles by the next nuclear reaction.
10B + h ---+ 7Li + +He(o) + 2.81 MeV (t)
They have high reactive biological effectiveness (RBE) and the range of them is less
than 10 pm in lissustr'zl.
However there are some problems to be solved on BNCT. One of the severest
problems is in the following: The number of patients treated is limited because a
nuclear reactor is required as a neutron source. The number of nuclear reactors
available for BNCT is only two in Japan. Moreover they are not specialized for medical
use. There are no plans to construct new nuclear reactors for BNCT. Various studies
thus started so far to realize acceleratorbased neutron source for BNCTIS'+I, because it
makes easy to access accelerator-based irradiation facilities near urban hospitals. And
the accelerator can reduce construction and operational cost. However, such kinds of
accelerators are not yet constructed because of various engineering problemsi decay
heat removal capability on target, stable control of high beam current, radioactivities
produced in such facilitiest5-7l.
The effectiveness of BNCT is estimated by making the product of 108
concentration, the cross section of toB and the thermal neutron flux intensitytsl. 11'rn"
concentration could be increased, the accelerator load could be decreased substantially.
Aiming at high accumulation of boron compounds into tumor tissues, drug delivery
system (DDS) is widely studied as an attractive intelligent technology to achieve the
selective delivery of medicine as well as boron. So far, several new efficient agents have
been propossdte-r+I. Especially Ozawa et al. reported about tumor bearing rats receiving
boronoporphyrins (BOPP) by convection-enhanced delivery (CED). CED of 1.5 mg BOPP
produced an average tumor boron level of 519 ppmlrot.
These novel boron agents tealize accelerator based BNCT with even a little weak
neutron source like a D-T neutron source. To confi.rm a possibility of BNCT with a low
neutron flux combined with a high boron concentration, a fundamental research is
indispensable.
In this study, we focus on the D-T neutron source as an accelerator-based thermal
neutron source. As for the D-T neutron source, there were some facilities available
worldwide. Because the D'T neutron source technology is already well established, the
performance is stable and the source can be utilized to various applications quite easily.
Also, it becomes simple to design a neutron moderator because the D-T neutron is
monoenergetic. In addition it is advantageous in design that in the D-T reaction no
gamma-rays are generated. However D-T neutrons have to be moderated and the
contribution of fast neutrons must be reduced since the incident energ"y is very high.
And the source neutron intensity is a little weak for BNCT.
Under these considerations, we aim at design and construction of a thermal
neutron field for fundamental BNCT experiments using a D-T neutron source. The
constructed thermal neutron field would be used to irradiate cultured cells or mice
combined with efficient boron agents to discuss possibility of the use of D-T neutron
sources for BNCT. Thus in this study, a thermal neutron field, not an epi-thermal field
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is constructed first for fundamental researches for BNCT. When studying the effect of
BNCT using cultured cells or mice, a pure thermal neutron field is preferred. However
clinical facilities should utilize epithermal neutrons because tumors are normally
located in deeper places. In the next step, an epi-thermal field will be planned to be
designed and constructed aiming at researches for practical applications for man.
The present neutron field should meet the following three design conditions.
Considering a necessary BNCT dose of a few Gy-Eq (equivalent dose), uniform
irradiation environment (temperature, humidity and so on) and use of mice (mice
should not be fixed for a long period), the exposure time must be limited to be shorter
than 2 hours (Design Requirement 1). The BNCT dose should be as high as possible. If
this is set to be several Gy-eq, the thermal neutron flux has to be more than 1 x 106
nlseclcm2 even if achieving a boron concentration being 10 times higher than before
(Design Requirement 2). Finally, it is obviously necessary to reduce the fast neutron
contribution as low as possible (Design Requirement 3), because fast neutrons, which
have cytotoxicity, don't have selectivity.
In this study, simulation calculations are carried out to design a thermal neutron
field meeting the 3 requirements described above using a D-T neutron source. The
results are used to construct a thermal column for experiments with small animals. As a
D-T neutron source, the Intense 14 MeV Neutron Source Facility, OKTAVIAN, of Osaka
University, Japan is utilized. The constructed thermal neutron field is characterized
and the obtained results are compared with the predicted values. We then examine
whether in uivo BNCT experiments would be possible using novel boron agents in the
present experimental setup. Finally, we discuss the future possibility of using D-T
neutron-based thermal neutron sources for actual BNCT in hospitals.
II. Design Calculation
1. Neutron Tbansport Calculation
In order to estimate the thermal (< O.S eV) and fast (> 0.01 MeV) neutron flux at the
irradiation area, simulation calculations were performed using MCNP-5 (A General
Monte Carlo N-Particle Tlansport Code)1151. ENDF/B-VI was used as a neutron cross
section libraryttol. Tlack length estimator (n+) tatty was used for calculating thermal
and fast neutron spectra. Reaction rates for 1e7Au (n, y) positioned in several places in a
box for irradiation of mice were calculated for comparison with the experimental results.
The calculation was performed using a virtual pure gold foil with the tally multiplier
card, FM, for the reaction type of (n, y), i.e., MT = 1,O2. The number of histories was 1 x
107, by which the statistical error can be reduced downto less than 5o/o. The absorbed
dose per source neutron from fast neutrons and photons was scored using an energy
deposition (F0) tatly.
2. Neutron Source
As a neutron source, Intense 14 MeV Neutron Source Facility, OKTAVIAN, of Osaka
University was used. The OKTAVIAN facility is a Cockcroft Walton type accelerator and
generates 14 MeV neutrons by eH (d, n) uHe reaction. The stably produced maximum
neutron source intensity is 
-1 x 1011 n/sec at present. Though the value is a little weak
for BNCT, it is sufficient to be used to fundamental researches.
3. Assumed Size of Irradiation Area
We designed a thermal insulation equipment using a styrofoam box for upcoming rz
vitro yradiation experiment and small animal holding fixture for upcoming in uivo
experiment. The holding fixture can hold 12 mice, which is sufficient value for
fundamental in vivoexperiments. The calculation was carried out with the idea of using
them. To put this equipment, the space of 20 x 20 x 20 cm3 was kept inside the thermal
51
neutron field. In the simulations the mice were assumed as water phantom containing a
small amount of salt.
4. Moderator and Reflector
The optimum amounts of moderator and reflector materials surrounding the irradiation
area were investigated by simulation calculations. Figure 3-1-1 shows basic
arrangement before the design calculations. The irradiation position (the distance from
the neutron source) and the thickness ofcarbon reflector were varied.
As a moderator high density polyethylene was put between the neutron source and
the irradiation area to moderate 14 MeV neutrons. Polyethylene has a high density of
0.95 and consists of only carbon and hydrogen. And it has a high hydrogen atomic
number density. Because their absorption cross sections are low and hydrogen thus has
an excellent moderation performance for neutron, polyethylene is selected as a neutron
moderator.
Also, neutrons leaking from the moderator have to be reflected to improve the
neutron flux intensity at the irradiation area. In this study graphite blocks were used as
the reflector. The thicknesses of the polyethylene and graphite reflector were
determined to meet the optimum condition by checking the thermal and fast neutron
flux intensities in the irradiation area.
In addition, a beryllium block was put between the polyethylene and the tritium
target for neutron multiplication by the Be (n, 2n) reaction. This reaction is available
only near the neutron source because it is a threshold reaction. Behind the sample area,
concrete and polyethylene blocks were put to shield and reflect neutrons passing
through the irradiation area.
III. Design of Thermal Neutron Field
Simulation calculations were performed to design an irradiation field so as to meet the
Design Requirement 1-3 in Chap. 1. Calculated thermal and fast neutron fluxes at the
irradiation area are shown in Figure 3-l-2 as a function of moderator thickness. The
error in the calculation was O.5% to 3.3%. The fast neutron flux decreases with the
thickness of polyethylene. The thermal neutron flux shows its maximum value at 5 cm,
and decreases if it becomes more than 5 cm. The ratio of thermal to fast neutron fluxes
is increasing as the moderator becomes thicker. Thickness of 65 cm is the highest in the
case of OKTAVIAN. However thickness of 65 cm is not acceptable because the thermal
neutron flux is too low. Finally, in this study the thickness of 20 cm was selected
considering the thermal neutron flux intensity. The nearer position seems to be surely
better from the standpoint of thermal neutron flux intensity, however, the fast neutron
dose becomes too high at positions nearer than 20 cm.
The thermal and fast neutron fluxes at the irradiation area are shown in Figure
3-l--3 as a function of the reflector thickness. As the reflector becomes thicker, the
thermal neutron flux increasesi meanwhile the fast neutron flux is constant. Because
the thermal neutron flux intensity slowly saturates for thickness more than 30 cm, 40
cm thick graphite reflector was adopted considering that it is actually difficult to
construct a bigger one than a 40 cm thick reflector.
In the case of 20 cm thick moderator and 40 cm thick reflector, the neutron
spectrum in the irradiation area is shown in Figure 3-1-4. Neutrons are moderated
adequately and Maxwellian distribution in the energy region of about 0.025 eV is
observed. The fast, epi-thermal and thermal neutron flux per source neutron were 5.4 x
10-5 n/cmzlsource neutron (s.n), 3.9 x l-0-5 n/cmzls.n and l-.6 x 10-4 n/cm2/s.n, respectively.
There is negligibly small difference in the thermal neutron flux between in the front
and back sides of the irradiation area.
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fV. Neutron Inadiation Experiment
1. Neufuon Flux Measwement
A thermal column as described in Figure 3-L-5 and 3-1-6 was built in the heavy
irradiation room of OKTAVIAN, and irradiation experiments were performed to
compare with the simulation calculation. In the experiment, the moderator thickness
was decided to be 20 cm. The fast and thermal neutron flux intensities were monitored
with activation foils. Niobium foils and gold foils were used for fast neutrons and
thermal neutrons, respectively. Niobium absorbs fast neutron via (ggNb(n,2n)szmffi)
reaction, which has an energy threshold of 9.1 MeV. Gamma rays of 934 keV were
emitted f1ery1 e2mffi. Niobium foils of L00 pm thickness were put in front of the tritium
target for D-T neutron, in the moderator and in the irradiation area. The dimensions of
the niobium foils for the three positions were 1 x 1 cm2, 5 x 5 cm2 and 3 x 10 cm2,
respectively. Gold foils of 50 pm thickness and 1 x 1 cmz were setup along the beam axis.
Also cadmium covers of 1 mm thickness were used together to determine the so-called
cadmium ratio. 934 keV and 4I2 keV y rays for niobium and gold foils, respectively, were
measured using a high-purity germanium detector (HpGe) (GMX-151-85-p, SEIKO EG
& G, Japan). Also, signals from a proportional counter were recorded in an MCS mode to
monitor the time-dependent neutron intensity and in order accurately to estimate the
amount of activation.
2. Radiation Dose Calculation
In this study we had assumed tlnat 12 mice are irradiated. The BNCT dose (Dexcr) at
the irradiation area was calculated to evaluate the performance of the constructed
thermal neutron field. The equivalent dose of BNCT, DeNcr, was calculated using the
following equation:
-DeNcr = (JBN x ZiN + Rsx IG x ,b) x 4l,ermarx T+ D+ Dy (2)
where, KN and Ka are the doses per unit fluences from nitrogen(2yo in weight of mouse
cell) and from boron (per 1 ppm)tsl, respectively. Nitrogen captures a thermal neutron
like as boron and produces a proton (taN (n, p) t+C). This reaction occurs as side reaction
in thermal neutron field because the reaction isn't threshold reaction. To calculate the
equivalent dose, the RBE 3.2 and 3.8 (RN and Rs) for Dr.r (the dose from nitrogen
reaction) and De (the dose from boron reaction) were used, respectivelytll. Cs, $thermal
and T are the intracellular boron concentration, the thermal neutron flux and the
irradiation time, respectively. The irradiation time was assumed to be 2 hours.
Activation foils were used to estimate intensities of the generated 14 MeV neutrons and
thermal neutrons ($tn",-r). And Dr and D, are the equivalent dose from fast neutrons
and the dose from gamma ray, respectively. They were estimated by MCNP-5
calculation and the measured value of the generated 14 MeV neutrons. In the
calculation, the areas in which there are mice were replaced with a cylindrical water
phantom and it was assumed that there is a tumor on the surface of a mouse. The RBE
of.2.3 was used[12]. KN and Ks are derived from the following equation.
K= Nt X Qi Xor (3)
where, Na is Avogadro's number, Q is the energy released per nuclear reaction, i.e.,
0.6 and 2.31 MeV for t+N(n, p) and roB(n, a) reactions, respectively and o is the
cross-sections of 1.75 barn for laN(n, p) and 3837 barn for roB(n, a) reactions (the
representative value for thermal neutron). The boron concentration of the tumor tissue
was assumed to be 300 ppm and that of the healthy tissue is 5 ppm. Although the
concentration is about 10 times higher than those expected in general BNCT cases, it
was reported in some papers[l0-rzl that it could be surely achieved. In this case the ratio
of tumor dose / normal dose is 53.
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V. Results and Discussion
1. Comparison Between Calculation and Measurement
Neutron irradiation was performed at the OKTAVIAN facility and the fast and thermal
neutron fluxes were measured with niobium and gold foils. The 14 MeV neutron source
intensity was 4.1 (+0.+) x 1010 n/s. The fast and thermal neutron fluxes at the sample
area were 1.9 x 1"06 (+O.Og) nlcmzls and 6.5 x 106 (-f 0.01) n/cmzls, respectively. These
results were compared with the calculation values as in Figure 3-1-7 as a function of the
distance from the tritium target. Table 3-1-1 compares the reaction rate of foils in the
sample area. The measured neutron fluxes were in good agreement with the calculation
results in the whole region (the ratio between simulation and irradiation experiment of
fast and thermal neutron fluxes were from 0.95 to 1.2, 0.85 to 1.0). Though there is a
tiny difference, it is small enough to discuss the dose of BNCT. It was determined by the
MCNP simulation that the neutrons in the irradiation area were moderated adequately
and the neutron energy distribution is Maxwellian in the energy region of about 0.025
eV. Thus the thermal neutron flux can be measured correctly by gold foil activation. On
the other hand, the activation of Niobium with fast neutron has an energy threshold of
9.1MeV. The threshold may lead to an underestimation of fast neutron flux because the
fast neutron in the energy region from 0.01 to 9.1- MeV cannot be measured.
From the comparison, it was confirmed that the simulation calculation worked
correctly. The irradiation dose could be hence estimated appropriately and the fast and
thermal neutron spectra can be quantified without measurement if only the
time-dependent neutron intensity of OKTAVIAN would be accurately monitored.
The irradiation dose of each sample could also be estimated from the calculated
results even if there are many samples (cells and/or mice) arranged in the irradiation
area. The thermal neutron flux was thus found to be constant in the irradiation area
within a difference less than 10%. It means the radiation doses can be kept constant. So
we can arrange many samples at a time in the same condition.
2.Irradiation Dose of BNCT
Equivalent doses were derived for cultured cell or small animals from the MCNP
calculation and the measured result. The equivalent doses were evaluated and
summarized in Table 3-L-2.
According to Makinodan, bone mzrrrow death did not occur at doses of 5 Gy-eqtl8l.
Hsue-Yin Hsua made sure that marrow stem cell survived 100 o% under 2 Gy-eq of
dosetlel. For these reasons, the normal tissue dose should be limited below 2 Gy-eq.
When the sample is positioned at 20 cm from the source, the equivalent dose of normal
tissue was confirmed to become much less than 2 Gy-eq. The toxicity for normal cell was
very low and mice would not be injured by fast neutrons.
It was reported that 3.7 Gy-eq dose shrinks the tumor of ratst2ol and that tumors
disappeared by 23 Gy-eq dosetzll. As is Table 3-L-2, the dose to the tumor tissue is 5.0
Gy-eq, which is enough large to confirm the anti-tumor effect in in vivo experiments.
Therefore the neutron flux from our setup is sufficient for BNCT experiments using
cultured ceII or mice. Now we are making a start on the experiment with cultured
cellst22l.
Also if 1 x 10tt n/s neutrons, which is the currently achievable neutron source
intensity at OKTAVIAN, are generated for 2 hours, the equivalent dose of tumor tissue
achieved 12 Gy-eq, which is effective value to treat tumor. On the other hand, the small
animals would be irradiated across the entire body and the dose is calculated in 1.0
Gy-eq. This value is adequately low to damage their healthlr2,rs,2ll and 1.0 Gy-eq dose
can't affects lipids peroxides in mouse serum[z4]. It can be expected that it would become
possible to carry out more precise experiments.
54
3. Feasibility of BNCT in a hospital with D-T neutron source
To realize a D-T based BNCT in a hospital, some existing problems should be solved.
The first one is to develop an epithermal neutron field, because the epithermal neutron
field is generally the best. The point is that the energy is too high to be moderated
keeping necessary epi-thermal neutron intensity and suppressing high energy neutron
contribution. However, thermal neutron fields using a D-T neutron source is intensively
under investigatiorl2s'271. There are thus sufficient possibilities to overcome the problem
in the near future.
Next, higher epithermal neutron flux of 10s n/cm2ls is needed according to IAEAt2sl.
In our approach, -10e n/cm2ls thermal or epithermal neutron field should thus be
needed with efficient boron agents. Generally D-T neutron sources can generate -1 x
10t2 n/sec using a rotating tritium target or gas target. The OKTAVIAN facility can
generate 3 x 10tz n/s, which is the full spec of the facility. The thermal neutron flux
would thus be 
-108 n/cm2ls at the irradiation area from the presently obtained result. It
means from the present results that BNCT with thermal neutrons for man could be
realized using the novel boron agents and a D-T neutron source.
Finally, careful handling of tritium, which is a radioisotope, is required. The
history of D-T neutron source goes back quite a long waytzol. The handling method has
been studied for nuclear fusion reactorsleo-szl. And tritium behavior in human body was
studied for years to control doses at OKTAVIAN facilitytssl. With these proven
techniques and careful treatments of tritium, there would be a possibility that BNCT in
hospitals would be realized.
VI. Conclusion
In this study, we designed and constructed a thermal neutron field with a D-T neutron
source to carry out basic BNCT experiments with cultured cell or small animals with
help of new boron agents. The neutron field was designed through simulation
calculations and verified with irradiation experiments. In the experiment, the 14 MeV
neutron source intensity was 4.1 x 1010 n/s and the thermal neutron flux at the
irradiation area was about 6.5 x 106 nlcm2ls. The BNCT dose is 5.0 Gy-eq for 2 hour
irradiation and the ratio between MCNP simulation and irradiation experiment of fast
and thermal neutrons were from 0.95 to L.2,0.85 to 1.0. In this case, fast neutron and
gamma ray doses were suppressed to be 0.31- Gy-eq and 0.023 Gy, respectively. It was
confirmed that the anti-tumor effect of BNCT could be observed in in yzyo experiment
using novel boron agents at the present neutron filed.
The series study showed a possibility of the D-TLbased BNCT if the source neutron
intensity would be larger than 
-1012 n/s.
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Figures
Table 3-1-1. Comparison of the foil reaction rate in the sample area (the distance from
the tritium target was 35 cm) between the calculation and experiment
niobium foil gold foil(fast) (thermal)
Ucmg/sl Ucms/sl
calculation       6.8E+04      3.lE+07
experiment      6.OE+04      2.8E+07
C/E
Table 3-1-2 Equivalent doses for small animals. The equivalent dose of BNCT was
calculated. The boron concentrations of normal and tumor tissue were assumed 5 and
300 ppm, respectively. The RBE 3.8, 3.2 and 2.3 for DB, DN and Df, respectively. The
irradiation time was assumed to be 2 hours.
De DN Dr Dy DeNcr
lGy-eql [Gv'eq] [Gv-eq] [cv] [Gv-eq]
norlnal tissue      7.8e‐2  1.le‐2       3.le‐1      2.3e‐      4.2e‐1
turnor tissue      4.7e+0      1.le‐2     3.le‐1     2.3e‐      5.Oe+0
1.11.1
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Figure 3-1-1 Basic arrangement for simulation calculations. Polyethylene blocks (dotted
area) were placed between tritium tatget and sample area to moderate 14 MeV
neutrons and graphite blocks Qray area) cover them to reflect neutrons. The moderator
and reflector thicknesses were variable.
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Figure 3‐1-4 Neutron spectrum in the lrradiation fleld.
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Figure 3-1-5 Vertical cross-section of the frnal experimental setup for neutron
irradiation.
100
Figure 3-1-6 Horiznntal sectional view of the final experimental setup for neutron
irradiation.
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Figure 3‐1‐7 Calculated thermal and fast neutrOn distrlbutions in the assembly
compared with the experimental results。 (Gray area(27 ～ 42 cO shows the
むradiation area.Lines are calculations.Gray square and black t五angle symbols are
neutron■lⅨes for thermal and fast energy regiOns,respect市eし).
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Section 2. In vitro and in vivo investigation of accelerator BNCT using a
non-viral vectori hemagglutinating virus of Japan envelope
I. Introduction
In the first section, I assembled a setup that achieved a thermal neutron flux of 6.5 x
l-06 n's-i cm-2 in the sample area. In this section, I describe the determination of. t}re in
uivo and in uitro effects of BNCT using low neutron flux with the same setup.
I first made HVJ-E-BSH, which is HVJ-E containing
mercaptoundecahydro-closo-dodecaborate (BSH). BSH accumulates selectively in brain
cancers due to the impaired function of the blood-brain-barrier (BBB)ttr; the selectivity is
not higher than that of the other commonly used drug,(L)- -dihydroxy-borylphenylalanine, called BPAt2l. However, the low selectivity is not a
problem when using IIVJ-E, which would extend the use of BSH to other cancers.
Although it cannot accumulate to as high an osmotic pressure, BSH, which has many
boron atoms. is also suitable.
In general, cells are seeded in culture plates for in uitro experiments. Six-well
(wide-space) culture plates were not appropriate for these experiments, as they require
a great deal of boron solution and produce a heterogeneous distribution of thermal
neutrons. However, if 96-well (small-space) culture plates were used, the number of
pre-seeded cells was quite low, diminishing the accuracy of the results. Therefore, I used
microtubes for irradiation. The adherent cells were trypsinized and suspended in a
buffer solution with boron agent. Because the conditions of the conjugate were stressful
for the cells, the time for which the cells remained healthy under these stresses was
measured and the irradiation time was set at 2 hours. The treated cells were
maintained in culture for 5 days to determine the magnitude of cell death during the
days following the irradiation. An appropriate number of pre-seeded cells was
determined before the experiment.
After the optimal conditions for the in vitro experiments were determined, the
intracellular boron concentration and the anti-tumor effect of BNCT using HVJ-E-BSH
were measured. After t}re in uitro experiments, in uivo experiments were conducted.
Cancer-bearing mice were produced and treated with BNCT using HVJ-E-BSH. The
tumor size and the survival time were measured and compared with those of untreated
mice.
II. Material and Method
1. D'T Neutron Source and Thermal Neutuon Field:
The intense 14 MeV neutron source facility OKTAVIAN of Osaka University was used
as a D-T neutron source. And set-up to make thermal neutron field was built based on
simulation calculation (Fig. 3-1- ). The detail was expressed in present studytsJ.
Briefly 20 cm of high density polyethylene was used for moderator and 40 cm width of
graphite cover the moderator and sample area.
2. Neufuon Flux Mesurement:
For D-T neutrons niobium foils were used and gold foils were for thermal neutrons.
Niobium foils of 100 [pml thickness were put in front of the tritium target, in the
moderator and in the sample box. The areas of the niobium foils for the three positions
were 1 x 1 [cm2], 5 x 5 [cm2] and 3 x 10 [cm2J respectively. Gotd foils of 50 [pmJ
thicknesses and 1 x 1 [cm2] were set up along the beam axis and the line perpendicular
to the axis to measure 2-dimensional flux distribution. Also cadmium covers of 1 [mm]
thickness were used together to determine the so-called cadmium ratio. 934 [keV] and
472 [t<eVl y rays for niobium and gold foils, respectively, were counted using a
high-purity germanium detector (HpGe) (GMX-15185-p, SEIKO EG & G, Japan). The
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absolute efficiency of the detector was measured with standard gamma-ray sowces.
Also, signals from a proportional counter were recorded in an MCS mode to accurately
estimate the amount of activation of the activation foils.
The neutron flux was calculated from the measurement result of HpGe using
following formula.
t I r i.l | 't cr' c'r'+L'r')1
Q= 2xN.c.rlo"x,lr- ,irfrl"s.e."!rf,r* -,i,- f l (r)L t r \ Jl
where 0: neutron flux, X: decay constant, N.C.: number of measured y-ray, o.
cross-section, ,Af number of atom of foiI, ti irradiation time, Tuzi half-life time of the
isotope, ,9.1.; self- absorption factor of foil, C.T.: cooling time and L.?: Iive time
The self-absorption factor of foil is
μ=1-exp14×ρ
×θ「) (2)
where ,4: absorption rate of y-ray, p density and d thickness. The value of 
-4 was
calculated from data base of National Institute of Standard and Technology using
interpolation method.
3. Cell Culture:
4.549 human lung cancer (adenocarcinoma) cell line and mouse lung cancer cell line
LLC were used for these studies. 4'549 cells were cultured in RPMI1640 (Sigma-Aldrich
Inc., MO) containing I0% serum (fetal calf serum, BioWest Inc., France), and
antibacterial agent (100 units/ml penicillin, and 0.1- mg/ml streptomycin (Nacalai
Tesque, Japan)). LLC cells were cultured in Dulbecco's Modified Eagle's Medium(DMEM (Sigma-Aldrich Inc., MO) containing 10 % FBS, 100 units/ml penicillin, and
0.1 mg/ml streptomycin. The cells were cultured at 37"C and 5 % QOz
4. Synthesis of IIVJ-E-BSH:
HVJ was inactivated by UV irradiation (99 mJ/cm2) using IfV cross-linker (Spectro
Linker XL-1000IJV cross-linker, Spectronic Corp.). Inactivated HVJ (3 x 10to parti-cles)
was mixed with 15 pL of 1-% protamine sulfate/ TE buffer (QIAGEN), 110.7 pL of.3%
BSH (STELLA PHARMA CORPORATION) and 40 pL of 3% TWEEN 80 (Nacalai
Tesque) and incubated 5 minutes at 4'C. The suspension centrifuged (t5,000 x g) for 5
minutes at 4"C. The supernatant liquid was removed and the pellet remained was
washed with BSS (Balanced Salt Solution, 10 mM Tlis-Cl, pH 7.5, 137 mM NaCl and 5.4
mM KCD. After this the suspension was centrifuged (tS,000 x g) for 5 minutes at 4"C
and the supernatant liquid was removed.
5. Preparation of CG-IfVJ-E'BSH:
3 x 1010 particles of HVJ-E-BSH was mixed with 125 mL of 40 mg/ml cationized gelatin(CG) polymer solution (Figure 3'2'D and incubated for 10 minutes at 4"C. The
suspension was centrifuged (15,000 x g) for 5 minutes at 4!C and the supernatant liquid
was removed.
6. Determination ofAdministration Time with IIVJ-E:
300 pL (2 x tOs cells/ml) of 4.549 cell was plated in a 24-well Plate (costarG) 3526,
Corning Inc.). 2+ hours later, when the cells had adhered to the plate, 25 StL of HVJ-E
added red fluorescent dye (PKH26-Red Fluorescent Cell Linker Kit for Phagocytic Cell
Labeling, Sigma-Aldrich Inc.) conjugate were injected to each well. After 0.5 - 4 hours
incubation, IIVJ-E conjugation was removed and washed with Phosphate Buffered
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Saline solution (PBS) (pH 7.4, Sigma-Aldrich Inc.). And the fluorescence of PKH26-Red(excitation: 551- nm, fluorescence: 567 nm) was observed with fluorescent microscopy
(BIOREVO BZ-9OOO, KEYENCE).
7. Concentration of Boron uptake by cells with IfVJ'E-BSH, CG-IIVJ-E-BSH,
B'liposome:
200 pL (t x tOa cels/well) of ,4'549 cell was plated tn a 24-well Plate. Four hours later,
when the cells had adhered to the plate, 100 pL of 100 ppm B boron compounds (BSH,
HVJ-E-BSH, CG-HVJ-E-BSH and B-liposome) were added to each well. TWo hours later,
the supernatant was removed and the cells were washed three times thoroughly with
phosphate buffered saline solution (PBS, pH 7.4, Sigma), and lysed with 1 mL of O.t%o
sodium dodecyl sulfate solution at 37'C for 2O minutes. After this the suspension was
diluted by adding 5 mL water and the intracellular uptake of boron was quantified
using ICP-AES (Inductively Coupled Plasma - Atomic Emission Spectrometry, ICP-7500,
Shimadzu Corp.).
8. Evaluation of the antitumor activity of BNCT in vitro:
100 pL of each of 100 ppm B boron agents (BSH, HVJ-E-BSH, CG-HVJ-E-BSH,
B-Liposome) was added to 100 pL of ,4'549 cell suspension (1 x 105 cells/ml). After 2
hours incubation, the cells were subjected to neutron irradiation for 2 hours. After
neutron irradiation, the boron agents were replaced with complete growth medium and
cultured with 6-well plate (microplate 6-well with Lid. code 3810-006, IWAKI, Japan).
After 5 days, the number of cells was counted to evaluate their sensitivity to BNCT.
T?ypan blue (Wako Pure Chemical Industries, Ltd., Japan) staining methods was used
to determine cell viability in this experiment.
9. Ttre Boron Concentration in Tumor fissue
Six-week-old male C57BL6J mice were purchased from Hamaguchi Laboratory Animals.
1x 10e LLC cells were injected subcutaneously in the dorsum of each mouse. Seven days
after cell injection, either 3.48 mg of BSH or 129 pg of BSH/ 5000 HAU of HVJ-E-BSH
was administered intravenously or via local infusion respectively. Thirty minutes or 2
hors later, the tumors were isolated and freeze dried. One hundred mg of fteeze dried
samples were burned with nitric acid (30%, 3 mL). The residues were dissolved to nitric
acid (6Yo,10 mL). The boron concentration was measured using ICP-AES.
10. Evaluation ofAnti'tumor Effect of BNCT in vivo:
To determine tumor volume, the greatest longitudinal diameter (length) and the
greatest transverse diameter (widtD from each tumor were determined using an
external caliper. Each tumor's volume, based on the caliper measurements, was
calculated using the following formula: tumor volume = length x width2 x 0.5t41. Seven
days after the injection of .4.431 cells, mice were randomized into four groups of at least
12 animals per group for the following treatments: (i) no treatmenti (ii) neutron
irradiation without boron agenti (iiil S.+S mg of BSH and BNCT performed or (iv) 129
pg of HVJ-E-BSH and BNCT performed. After treatment, the mice were monitored
daily and their tumor volume was measured thrice a week.
III. Results
1. Chronological change of intracellular fluorescent dye:
The fluorescent images of PKH26-RED were shown in Figure 3-2-2. The fluorescent
intensity was brightened up with time to 2 hours. After 2 hours, the intensity became
stable.
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2. Intracellular Boron Concentration:
The relationship between the boron agent and its intracellular uptake is shown in
Figure 3-2-3. The value using BSH was lower than limit of determination. The value
using HVJ-E, CG-HVJ-E-BSH or B-Liposome was 1.00, 0.85 or 0.68 pg/100 cells
respectively. The novel boron agents decupled the boron concentration comparing with
BSH.
3. Measurement of fast and thermal neufoon at the sample box:
The fast neutron flux was 3.76 (+0.18) x 10s n/cmzlsec. The thermal neutron flux was
1.69 (+0.37) x 100 n/cmzlsec and Cd ratio was 5.03 (+f .05).
4. Evaluation of the antitumor activity of BNCT in vtro:
The cytocidal effects of BNCT were evaluated for each boron agent. The results are
described in Figure 3-2-4. The figure shows the proportion of cell number compared
with untreated cell number. OnIy when using HVJ-E-BSH, the cytotoxicity of BNCT
was observed with significant differences.
5. Boron concentration in tumor tissue:
Figure 3-2-5 showed the result of boron concentration in tumor tissue. The
concentration using IIVJ-E was less than the concentration using BSH.
6. Evaluation of the antitumor activity of BNCT in uivo:
The antitumor activity of BNCT was evaluated in in uivo experiment. The tumor size
modification and Kaplan-Meier survival curve of BNCT was shown in Figure 3-2-6 and
3-2-7 respectively. Any difference was observed.
fV. Discussion
As shown in Fig. 3-2-4, BNCT cytotoxicity was observed when HVJ-E-BSH was used. I
hypothesize that the increased intracelluiar boron concentration was responsible for the
anti-tumor effect. The equivalent dose of BNCT can be estimated from the product of
neutron fluence and boron concentration.
Currently, nuclear reactors are used as the neutron sources for BNCT. Various
problems with this system have been described. Accelerator-based neutron sources for
BNCT have been developed in several countriests-rol. However, to date, such kinds of
accelerators are not yet realized because of weakness of accelerator-based neutron
source. Development of effective accelerator-based BNCT is important for both
experimental study and therapy. I therefore proposed low-neutron-flux BNCT with a
combination of an accelerator neutron source and high intracellular boron concentration
obtained with a drug delivery system.
The time for transition of contents from HVJ-E into cells was observed using
HVJ-E containing red fluorescent dye (Fig. 3-2-3). The fluorescence increased notably
between 0.5-2 hours but little between 2-4 hours. Therefore, it seems that HVJ-E
requires less than 2 hours to deliver the drug. In this study, the transition time was
assumed to be 2 hours.
The experiments measuring intracellular boron concentration demonstrated that
the novel boron agents (HVJ-E, CG-HVJ-E, and B-liposomes) increase boron
concentration more than lO-fold over that obtained with BSH alone (fig. a-Z-a). CG
adds a positive charge to the HVJ-E surface and thus increases its association with the
cell surfac"tttl, which is negatively charged. However, this effect was not observed in
this experiment. Therefore, the usefulness of the electrostatic attraction between
CG-HVJ-E-BSH and the cell surface should be reconsidered.
The anti-tumor effect of BNCT was measured using the MTT assay (Fig. 3-2-5).
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The magnitude of the effected correlated with the boron concentration. It is not known
whether the cytotoxicity is affected by the mode of uptake. Although the cellular uptake
Ievels of CG -HVJ-E-BSH and HVJ-E'BSH were almost the same, the cytotoxicity of
CG-HVJ-E-BSH was less. In contrast, B-Liposomes produced the same cytotoxicity as
HVJ-E despite delivering a lower boron concentration. The different subcellular
localization of the drug may produce different effects on the DNA, subcellular organelles,
or cytokine production related to the induction of cell deathtl2'131. CG-HVJ-E-BSH and
B-Liposomes exhibited cytotoxicity even in the absence of neutron irradiation. This drug
toxicity may also interact with the BNCT effect.
In the neutron irradiation experiments, the equivalent dose of BNCT was
calculated with the RBE values of o rays and Li rays equal to 3.0t141 (Table 3-2-1). The
fast neutron flux was 3.76 x 10s n/cm2ls, the equivalent dose of fast neutrons calculated
with LET was7.44 x 10-14 J/kg/(n/cm2), and the RBE of recoil nucleus - 2.3t151 was 4.47
x 10-4 Gy-Eq. These values are not effective for killing cancer cells. However, the
equivalent doses of novel boron agents were adequately high and produced sufficient
BNCT effect for the cytotoxicity to be detectable.
The relationship between the dose and the cytotoxicity was same in previous
studiestl6'171 that is, sufficient to observe the cytocidal effects but insufficient for actual
therapy. The equivalent dose in the present case was not sufficient for actual therapy.
However we know that the stably produced maximum neutron intensity for a D-T
neutron source such as OKTAVIAN is on the order of 10rz n/s. In addition, in our
previous work, the use of HVJ-E-BSH achieved intracellular boron concentrations of up
to 100 ppm. Considering these facts and the presently obtained cytocidal effects, it
should be possible to use a D-T neutron source as a thermal neutron source for BNCT.
In the in uivo experiments, no growth inhibition of tumor tissue or survival
advantage was observed due to the failure of HVJ-E-BSH to enhance the boron
concentration. Fig. 3-2-6 shows the results for the boron concentration in tumor tissue.
Contrary to my expectations, the boron concentration produced using HVJ'E'BSH was
less than that produced using standard BSH. Delivery of BSH by IIVJ-E did not achieve
a sufficiently high boron concentration in the tumors to support BNCT treatment.
However, the concentration was sustained 2 hours after injection, which is an
advantage of HVJ-E.
I hypothesize that the low affinity of LLC cells for HVJ-E is the reason for the low
boron concentration of lfVJ-E-treated tumor tissue. HVJ-E binding to the cell strface is
mediated by an acetyl-type sialic acid recognized by the HN protein on the vectortlsl but
LLC cells express little sialic acid at the cell surface. In the HVJ-PDT experiment
(Section 2-I), tlne LLC cell line took up less photosensitizer than did the other cell lines
despite their high growth rate. In general, human cancer cells strongly express sialic
acid. Therefore, the BNCT effect produced by HVJ-E-BSH should be measured in a cell
line that expresses sialic acid similarly to human cancer cells.
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Figures
Table 3-2'1. Equivalent dose (RBE-Gy) of BNCT
BSH   HVJ‐E‐BSH  CG‐HVJ‐E BSH  B‐Liposome
(.sSlll″Ed<°19 3。4(■0.07) 2.9(±0。13) 2.3(■0.04)
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Figure 3-2-1. Chemical structure of cationized gelatin.
Figure 3-2-2. Fluorescence microscopic images of 4'549 with PKH26-RED. Images of
PKH26-RED obtained at 0.5, I,2,4 hours after the addition of the probes. Bar = 100
pm.
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BSⅡ 則 ‐E‐BSH CG‐田 募 卜Liposome
BSH
Figure 3‐2-3 1ntracellular uptake of Boron. Intracellular concentration of boron is
expressed against boron compound.The broken line indicates quantification lillnits(0.06
mg/1o6cellS).
CONtTOI BSH IIVJ-BSH CG.}IVJ. B
FBSH Liposome
Figure 3-2-4. Antitumor effect of BNCT measure by trypan blue dyeing. The cell
survival rate (o/o) compared with the cell number of B-negative and neutron-negative
sample is expressed.
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Figure 3‐2‐5.Boron concentration in tumor tissue.
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Figure 3-2-6. The tumor growth mediated BNCT in LLC tumor. The tumor volume is
expressed against elapsed days. The symbol indicates: .; no treatment, ri neutron
irradiation without boron agent, a; 3.48 mg of BSH and BNCT performed and o; 729 Stg
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Figure 3-2-7. An analysis using a Kaplan-Meier survival curve of BNCT in LLC tumors.
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Section 3. Development of the in'vitro experiment of BNCT
I. Introduction
In this section, I describe strategies for correcting the problems of the previous in uivo
experiments. In the previous section, no effect of BNCT was observed in tumor-bearing
small animals. This poor result was thought to be due to the lack of affi.nity of LLC cells
for HVJ-E.
Because HV」‐E‐BSH (HVJ-E containing
mercaptoundecahydro-closo-dodecaborate (BSH)) was administered via local infusion,
the affinity of the tumor cells for HVJ-E is importanttl,zl. In section 1 of chapter 2, the
intracellular concentrations of photosensitizer in each cell line were compared, and
some differences were observed. LLC took up less photosensitizer than did the other cell
Iines. The lower uptake may lead to less accumulation. Inclusions enter the excretory
pathway independently. BSH is impervious to molecular degradation. The BSH uptake
abilities of each cell Iine should also be compared.
The setup was also improved by the use of deuterium water. The importance of
deuterium water was indicated in section 1. It is highly possibility that this allows the
thermal neutron flux in the sample area to be increased without increasing the fast
thermal neutron flux. A reservoir was made from high-density polyethylene, and
neutron transport was simulated when this reservoir was filled with deuterium water.
II. Material and Method.
1. Synthesis of IilrJ-E-BSH
HVJ was inactivated by UV irradiation (99 mJ/cm2) using IJV cross-linker (Spectro
Linker XL-1000IfV cross-linker, Spectronic Corp.). Inactivated HVJ (3 x 10to parti-cles)
was mixed with l-5 pL of !%o protamine sulfate/ TE buffer (QIAGEN), ILO.1 pL of 3%
BSH (STELI"A PHARMA CORPORATION) and 40 pL of 3% TWEEN 80 (Nacalai
Tesque) and incubated 5 minutes at 4"C. The suspension centrifuged (1S,OOO x g) for 5
minutes at 4!C. The supernatant liquid was removed and the pellet remained was
washed with BSS (Balanced Salt Solution, 10 mM Tlcis-Cl, pH 7.5, 137 mM NaCl and 5.4
mM KCD. After this the suspension was centrifuged (1S,OOO x g) for 5 minutes at 4"C
and the supernatant liquid was removed.
2. Cell culture
The cell lines used in this study were the human lung cancer cell line 4549, the murine
melanoma cell line 816 the mouse colon carcinoma cell line CT26 and the mouse Lewis
Iung adenocarcinomas cell line LLC. The ,4'549 cells were cultured in RPMI-1640
medium (Sigma-Aldrich Inc.) containing l0 o/o fetal bovine serum (FBS, Biowest Inc.,
France), 100 units/ml penicillin, and 0.1 mg/ml streptomycin (Nacalai Tesque, Japan).
The 816, CT26 and LLC cells were cultured in Dulbecco's Modified Eagle's Medium(DMEM) (Sigma-Aldrich Inc.) containing 10% FBS, 100 units/ml penicillin, and 0.1
mg/ml streptomycin. The cells were cultured at 37"C and 5%o COz.
3. Concentration of Boron uptake by cells with IIVJ-E-BSH, CG'[IVJ-E-BSH,
B-liposome
200 pL (l- x 10e cels/well) of ,4549 cell was plated in a 24-well Plate. 4 hours later, when
the cells had adhered to the plate, 100 pL of 100 ppm B boron compounds (BSH,
HVJ-E-BSH, CG-HVJ-E-BSH and B-liposome) were added to each well. TWo hours later,
the supernatant was removed and the cells were washed three times thoroughly with
phosphate buffered saline solution (pgs, pH 7.4, Sigma), and lysed with 1 mL of O.l%
sodium dodecyl sulfate solution at 37"C for 2O minutes. After this the suspension was
diluted by adding 5 mL water and the intracellular uptake of boron was quantified
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using ICP-AES (Inductively Coupled Plasma - Atomic Emission Spectrometry, ICP-7500,
Shimadzu Corp.).
4. Neutron Tbansport Calculation
In order to estimate the thermal and fast neutron flux at the irradiation position,
simulation calculations were performed using MCNP'5I31 (A General Monte Carlo
N-Particle Thansport Code). ENDF/B-VII4I was used as a neutron cross section library.
Tback length estimator tally, F4, was used for calculating thermal and fast neutron
spectra. Reaction rates for 1e7Au (n, y) positioned in several places in a box for
irradiation of mice were calculated for comparison with the experimental results. The
calculation was performed using a virtual pure gold foil with the tally multiplier card,
FM, for the reaction type of (n, y), i.e., MT = 7O2. The number of histories was 1x10?.
5. D-T Neutron Source and Ttrermal Neuhon Field
The intense 14 MeV neutron source facility OKTAVIAN of Osaka University was used
as a D-T neutron source. And set-up to make thermal neutron field was built based on
simulation calculation (Figure 3-3-1).
6. Neutron Flux Mesurement
FFor D-T neutrons niobium foils were used and gold foils were for thermal neutrons.
Niobium foils of 100 pm thickness were put in front of the tritium target, in the
moderator and in the irradiation position. The areas of the niobium foils for the three
positions were l- x 1 cm2, 5 x 5 cm2 and 3 x 10 cm2 respectively. Gold foils of 50 pm
thickness and l- x 1 cm2 were set up along the beam axis and the line perpendicular to
the axis to measure 2-dimensional flux distribution. Also cadmium covers of 1 mm
thickness were used together to determine the so-called cadmium ratio. 934 keV and
4L2keY y rays for niobium and gold foils, respectively, were counted using a high-purity
germanium detector (HpGe) (GMX-15185-p, SEIKO EG & G, Japan). The absolute
efficiency of the detector was measured with standard gamma-ray sources. Also, signals
from a proportional counter were recorded in an MCS mode to accurately estimate the
amount of activation of the foils.
7. Radiation Dose Calculation
In this study we had assumed that 1,2 mice are irradiated. The BNCT dose (DsNcr) at
the inadiation area was calculated to evaluate the performance of the constructed
thermal neutron field. The equivalent dose of BNCT, DeNcr, was calculated using the
following equation:
.DeNrcr=(ft.Txy'fN+ Rsx I{Bx C}) x frhermar x T+D+ 4 Q)
where, KN and Ks are the doses per unit fluences from nitrogen(2oA in weight of mouse
cell) and from boron (per 1- ppm)trt, respectively. Nitrogen captures a thermal neutron
Iike as boron and produces a proton (t+N (n, p) taC). This reaction occurs as side reaction
in thermal neutron field because the reaction isn't threshold reaction. To calculate the
equivalent dose, the RBE 3.2 and 3.8 (RN and Re) for DN (the dose from nitrogen
reaction) and De (the dose from boron reaction) were used, respectivelytol. CB, (fthermal
and T are the intracellular boron concentration, the thermal neutron flux and the
irradiation time, respectively. The irradiation time was assumed to be 2 hours.
Activation foils were used to estimate intensities of the generated 14 MeV neutrons and
thermal neutrons ($rn""-u). And Dr and D, are the equivalent dose from fast neutrons
and the dose from gamma ray, respectively. They were estimated by MCNP-5
calculation and the measured value of the generated 14 MeV neutrons. In the
calculation, the areas in which there are mice were replaced with a cylindrical water
phantom and it was assumed that there is a tumor on the surface of a mouse. The RBE
76
of.2.3 was used[t7]. KN and Ks are derived from the following equation.
K=Nex QiXor (3)
where, Na is Avogadro's number, Q is the energy released per nuclear reaction, i.e.,
0.6 and 2.31- MeV for 1aN(n, p) and toB(n, a) reactions, respectively and o is the
cross-sections of 1.7b barn for r+N(n, p) and Bg37 barn 1o" roB(n, cr) reactions (the
representative value for thermal neutron). The boron concentration of the tumor tissue
was assumed to be 300 ppm and that of the healthy tissue is 5 ppm. Although the
concentration is about 10 times higher than those expected in general BNCT cases, it
was reported in some paperstT-el that it could be surely achieved. In this case the ratio of
tumor dose / normal dose is 53.
III. Result
1. Intracelluler Boron Concentration
The relationship between the boron agent and its intracellular uptake is shown in
Figure 3-3-2. When the concentration of HVJ-E-PPIX suspension was over 50 pM, the
816 cells took up more PPIX than the other cells especially LLC.
2. Estimated Value of Simulation Calculation
Monte Calro simulation was operated to estimate the fast and thermal neutron flux.
The value predicted by the calculation was 4.4 x 10-5 n-/cm2lsource neutron and2.9 x 10 a
n/cm2lsource neutron respectively. Though the predicted fast neutron flux was increased,
the rate was small. On the other hand the thermal neutron flux was expected to
improve two times higher than current set-up.
3. Comparison between Calculation and Measurement:
Neutron irradiation was performed at the OKTAVIAN facility and the fast and thermal
neutron fluxes were measured with niobium and gold foils (Table 3-3-1, Figure 3-3-3).
The 14 MeV neutron source intensity was 3.2 x 1010 n/s. The fast and thermal neutron
fluxes were 6.1 x 105 and 8.9 x 100 nlslcm2 respectively and Cd ratio was 6.7. The
measured neutron fluxes were in good agreement with the calculation results in the
whole region.
fV. Discussion
The intracellular boron concentration of each cell line was measured, with 816 cells
found to take up the most boron. Although the difference in uptake rates between 816
and LLC cells was not large, the difference would be magnified in iz uivo expenments
because the uptake need not take place as quickly in vitro.In the tumor tissue of small
animals, HVJ-E moves through with the flow of blood, making its ability to adhere to
tumor cells even more important. While t}re in vitroexperiments reported herein did not
allow me to evaluate the tumor accumulation of the boron agent, it is highly possible
that the accumulation was in fact improved.
The setup was also improved by the use of deuterium water, which increased the
thermal neutron flux. Rat tumors have been reported to shrink after a radiation dose of
3.7 Gy'eqttol and disappear after a dose of 23 Gy-eqtttl Boron concentrations of 120 ppm
and 1050 ppm would be required to achieve the equivalent doses with the thermal
neutron flux produced by this experiment. Although it is not known whether HVJ-E can
deliver such concentrations, it seems likely, as it has been reported that the boron level
produced by CG-HVJ-E-BSH (a HVJ-E BSH-spiked cationized gelatin) was 35 times
higher than that produced by BSH alone. There are also other boron agents that have
already reached a concentration of 519 ppm f6161t7J. Therefore, these novel boron
agents could be used to conduct in vivo experiments on accelerator-based BNCT.
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Figures
Table 3-3-1. Results of the measurement of the I rays from the activation foil.
Experimental value
generated 14 Mev neutron
fast neutron in sample area
thermal neutron in samaple area
Cd ratio
3.2×1010
6.1×105
8.9 × 106
6.8
2.3x100
1.l x 100
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Figure 3-3-1. Experimental set-up for neutron irradiation. Deuterium water was placed
between tritium target and sample area to moderate 14 MeV neutrons.
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Figure 3-3-2. Intracellular uptake of boron. Intracellular concentration of boron in each
cell line is expressed. The value of 816 was the highest.
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Figure 3-3-3 Flux of the thermal and fast neutron and the ratio of thermal/ fast in the
sample box using different moderator calculated by MCNP-5i polyethylene (PE) and
heavy water (DzO).
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Chapter 4. DNA Damage from High LET Radiation Using Escherichia coU
In Chapter 3, equivalent dose was calculated to evaluate the boron neutron capture
therapy (BNCT) effect, and the value was compared with those from other studies on
the same cell line. Although the RBE value of each nuclear reaction was determined in
the previous study, some points remain unclear. To accurately calculate the dose and
administer treatment with the least side effects, the radiological consequences need to
be precisely assessed.
In PDT treatment, reactive oxygen species induce apoptosis or necrosis via cell
membrane or organelle damagetrl. n the other hand, radiation damages DNA in BNCT
treatment. DNA damage-induced cytotoxicity occurs via 2 pathways (indirect and direct
effects)t21.
In the indirect effect, molecules except the target absorb radiation energy and
produce active substances such as free radicals whose toxicity elicits a biological effect.
In aqueous solution, radiation interacts with the external medium. It may break the
bonds that hold the water molecule together, producing fragments such as hydrogen
and hydroxyl ions. These fragments may recombine or may interact with other
fragments or ions to form compounds, such as water, which is not harmful to the cell.
However, they could combine to form toxic substances, such as hydrogen peroxide,
which can contribute to the destruction of the celll31. Particularly, hydroxyl and
hydroperoxy radicals readily react with DNAt4l.
The interaction of radiation with the atoms of DNA or other cellular components
critical to the survival of the cell is referred to as a direct effect. Such an interaction may
affect the ability of the cell to reproduce and, thus, survive. If enough atoms are affected
such that the chromosomes do not replicate properly, or if there is significant alteration
in the information carried by the DNA molecule, then the cell may be destroyed by
"direct" interference with its life-sustaining system. The position at which the radiation
is absorbed does not necessarily correspond to the breakpoint. The absorbed energy is
sometimes transported to other bonds or molecules, where it breaks weak bondst5,6l.
DNA is the most important material and serves as the master blueprint for the cell.
There is considerable evidence suggesting that DNA is the primary target for cell
damage from ionizing radiation. If a cell is exposed to radiation, the probability of the
interaction between radiation and the DNA molecule is very small because these critical
components make up a small part of the cell. However, cells are mostly composed of
water. Therefore, there is a much higher probability of radiation interacting with the
water. The proportion of direct effects depends on the radiation type and energy, and
high linear energy transfer (LET) radiation produces more direct effects. Because
indirect effects produce discrete lesions by random energy deposition of the diffusing
radical, they are easy to repair. Direct effects produce closely spaced lesions forming
clustered DNA damage. Clustered DNA lesions have been suggested to be more difficult
to repair and are, in general, a form of DNA damage that is repair-resistant or
non-repairable, with a high mutagenic potential. Therefore, they are highly significant
biological endpoinlstz,sJ.
BNCT involves a B (n, o)-Li reaction and mainly produces ion beams that damage
cells. Ion beams generated by BNCT exhibit a Bragg peak and high LET. That leads
high dose, low Oxygen Enhancement Ratio (OER) and high specificity. However, the
RBE value of these ion beams remains unclear. For example, the value of the radiation
weighting factor is 20tsl. Although this value is set slightly high from a radiation
protection perspective, various values have been reported in BNCT studies and no
consensus has been reached.
The major factor in the lack of a consensus is insufficient knowledge of clustered
damage. If the absorbed dose is same value, clustered damage inhibits DNA repair and
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increases the effects on the cell. Therefore, I examined the mechanisms underlying the
cellular disorder induced by y-rays and o-rays, which are generated in the BNCT
reaction.
In this study, I used Escherichia coli(8. col), a model organism used to investigate
cellular responses to ionizing radiation. It possesses several repair pathways, such as
base excision repair and homologous recombination, to cope with various types of
radiation-induced DNA damage, which are relevant to the biological consequences of
ionizing radiationttol.
E. coli is likely to mutate, which can be easily detected using various methods. I
used phenyl-B-d-galactose (P-GaI), 5-bromo-4-chloro-indolyl'galactopyranoside (X-gal),
and antibiotics. P-gaI and X-gal detect mutations in the lac operon, which is a suite of
genes whose products metabolize lactose. It consists of 3 adjacent structural genes: IacZ,
IacY, and IacA. The lac operon is regulated by several factors, including the availability
of glucose and lactose. In its natural environment, the lacoperon allows for the effective
digestion of lactose. The cell can use lactose as an energy sorrrce by producing the
enzyme B-galactosidase, which digests lactose into glucose and galactose. However, it
would be inefficient to produce the enzyme when there is no lactose available, or if there
is a more readily available energy source, such as glucose. The lacf gene coding for the
repressor lies near t}:e lacoperon and is always expressed. In the absence oflactose, the
repressor binds very tightly to a short DNA sequence, called t}re lac operator [rrJ 
,
downstream of the promoter near the beginning of IacZ. P-gal is a substrate for
B-galactosidase, but does not inactivate the repressor and is, therefore, not an inducer.
Because wild'type cells produce very little B-galactosidase, they cannot use P-Gal as a
carbon and energy source. Mutants lacking the repressor are able to grow on P-Gal.
Thus, minimal medium containing only P-Gal as a source of carbon and energy is
selective for repressor and operator mufanlstr2l X-gal is used together with
isopropyl-B-d-thiogalactoside (IPTG), which is an inducer of the lac operon in
physiological studies. Cells that express IacZmetabolize X-gaI, and are dyed bluelte,t+t.
The antibiotics rifampicin and streptomycin were used in this study. Rifampicin
inhibits RNA polymerase, which is responsible for binding to a strand of DNA and uses
it as a template to construct a strand of mRNAttsl. Streptomycin is bactericidal in action.
It inhibits protein synthesis by irreversibly combining with the 30S subunit of the7OS
ribosome. Specifically, it binds to the S12 protein involved in the initiation of protein
synthesis. Cells harboring mutations in the binding protein can be detected using
medium containing these antibioticstl6l.
The radiation sensitivities of wild-type E. coli and each mutant were compared
using survival and mutation frequency measurements. In section 1, the relationship
between LET and DNA repair function is examined. Wild type and mutants were
irradiated with X-rays or He-rays and the survival rate and mutation frequency were
measured. In section 2, I examined the effect of medium on the radiation sensitivity
observed in section l-. Because rich medium makes wild-type E. coliresistant to X-rays,
the mechanism and relationship with LET were examined.
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Section 1. Difference of radiation effective depending on LET
I.Introduction
There are many types of radiation and each has its own mechanism of action. Especially,
the effects of high-linear energy transfer (lnt) radiation are different from those of
X-rays or y-rays. High-LET radiation tends to inflict great damage on DNA via direct
effects and the damage is easily clustered. Because clustered DNA damage is difficult to
repair, high-LET radiation has a significant impact on cellstll.
To determine the difference, I compared the effects of He-ray and x-ray. Wild-type
Escherichia coli(8. col) andits mutants were used, because E. colilacking the gene for
DNA repair can be easily generated from wild-type cells. Table 4-L-1 shows the genes,
the protein products of the genes, and the repair mechanisms associated with the genes
used in this study. The mechanisms described in Table 1 are the main DNA repair
systems in E. coli
Nucleotide excision repair (Nnn) is a highly versatile and sophisticated DNA
damage removal pathway that counteracts the deleterious effects of a multitude of DNA
lesions, including the major types of damage induced by environmental sources. The
most relevant lesions subject to NER are cyclobutane pyrimidine dimers and
6,4-photoproducts, the 2 major kinds of injury produced by the shortwave UltraViolet
(UV) component of sunlighttzJ.
DNA mismatch repair (MMR) is a repair system that removes erroneous
insertions, deletions, and mis-incorporation of bases during DNA replication, usually in
the newly synthesized strandt3,4l.
Homologous recombination is the exchange or replacement of a DNA region by its
homologous DNA sequence from the homologous chromosome or the sister chromatidtsl.
Homologous recombination is the major process for repairing double-strand breaks
(DSB) in bacterial DNAt6,7l.
The SOS response is a set of inducible physiological reactions that enable cells to
survive after treatment with various DNA-damaging agentsts,el. RecA and LexA, which
are the products of the recA and IexA genes, respectively, regulate the induction of the
SOS response in cells after exposure to genotoxic stress. LexA is a repressor that binds
to a motif called the SOS box located upstream of the regulated genestlol. RRecA is
essential for homologous recombination because it binds to single-stranded DNA, which
is generated when the replication fork encounters replication-blocking lesions or after
exonucleolytic processing of DSBs, and forms a nucleofilament to facilitate the search
for a homologous sequencelnl. RecA also has a regulatory role: it becomes activated after
binding to DNA, and in its activated form degrades LexA. Null mutants of recA show no
SOS response[10]. The IexAS strain, which produces a mutant IexAthat is resistant to
degradation by RecA, also does not exhibit an SOS response.
DNA helicase I (T!raI) is a bifunctional protein encoded by the F-plasmidtrzl and
contains 3 functional domains essential for the transfer of bacterial genes during
conjugationtl3-ls1. F-plasmid transfer is initiated by endonucleolytic cleavage of the DNA
strand. This origin-specific nicking event is modulated by the product of tralir6'171. If the
nick is produced near a single-strand breakpoint, it may behave like clustered DNA
damage.
In this study, mutations were generated in the above-mentioned DNArepair genes.
To reveal the effect of high-LET radiation, wild-type E. coli and its mutants were
irradiated with X-rays or He-rays and their sensitivities were measured. The survival
rate and mutation frequency produced by the irradiation were compared.
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IIo MATERIALS AND METHODS
l.Bacterial strains:
The wild‐type strain CSH100 and strains S1/1R6318, JW5855‐2, CSHl15, CC104,
JW399671, and DⅣ149 were obtained from the a coli Genetic Stock Cёnter9 Yal
Un市ersity.CsH100醸虚 Was constructed by transducing a睦盤 :Chm allele from strain
SMR6318 using Pl phage.CSH100rθθθ w S COnstructed by transducing a r“o:Kan
allele from strain」W5855‐2,CSH100″υムSwas constructed by transducing a′ηυιS:Tet
allele from strain CSHl15″υ憂ちand CSH100″vAwas constructed by transducing a
″7F4::Chnl allele from strain cc104υJrAusing Pl phageo CSH100Fθα4 was constructed
by transducing a Fθι4::CmR allele frOlln strain A」W807 using Pl phage.AJW807 was a
kind gift from Dr.A.Jo Wolfe.CSH100」b“θ was cOnstructed in 2 steps.First,
力r2」Br&″F from JW3996‐l was transduced into DL149。 Second,the Jα乙4θ allele was
co‐transduced with■2」η31■CIIF into CSH100宙a Pl transduction.The transfer Of the
回 θ allele was verified by PCR amplification and subsequent i物騎,I digestio  of th
■enlocus[181.
2.Growth ofcells
Cells were grown in minimal medium(10.5g/L of K2HP04,4.5g/L of KI12P04,lg/L of
(NHD2S04,0.5g/L of sodium citrate,l mM MgS04,5×10‐4%thiamine hydrochloride,
and O.2%glucose)。For irradiation, cells were prepared according to the protocol of
L[aezawa[191.Briefly logarithlnic cells were prepared by diluting an overnight culture
50‐fold f01lowed by incubation for several hours at 37°C to 6btain a cell density of
approximately 4× 108 cellS/1nL.Logarithlnic cells werё washed and r suspended in
saline solution(0.15 ]Ⅵ NaCD, and were placed on a nitrocellulose membrane
(GSWP01300;Millipore,Co.Ltの.
3,X‐ray iradiation
X―rays were generated using Soft X‐ray generator with a tungsten target(SOFTEX
Ⅳl‐150WE;SOFTEX Co.,Lt(D.The peak electrical voltage was set at 150 kVp and the
current was set at 6 mA.The dose rate was 27.9 Gy/min,which was determined using a
Fricke dosimeter.
4.He‐ion irradiation
The enёrgy of He ions(50 MeVn generated by the AVF cyclotron at Takasaki lon
Accelerators for Advanced Radiation Application was reduced by placing an Ni filter of
300-llnl thickneSs in front of the sample.The average LET of the sample,estilnated
using ELOSS code,a llnodified OSCAR code[201,and was 889 keV/11m.To calculate the
absorbed dose, particle fluence was measurёd usi g a CR39 plastic dosilneter
(HARZLAS TD‐1;Fuku宙Chemical lndustry lnc.,JapaD.The dose rate was 8 10
Gy/sec.
5。Meaglrement ofs―ival and mutation iequency ofcells
After irradiation,cells were collected and suspended in saline solution and a fraction
was immediately plated on minimal or selection plates containing 15 g/L agar.The
number of survlvOr colonies was determined and divided by the number of
non―i[radiatod colonies to deterllnine the survivor fractiOno We selectedルθ」llnutants on
llninimal medium containing O.20/O P‐gal as the sole carbon source, as described
elsewhere[21]. After exposllre to X‐ray むradiatio五, cell suspensions were plated on
minimal plates containing 100 mg/mL streptomycin or rifampicino After incubation at
37°C for 40 h,the streptomycin‐or rifampi n‐res stant colonies were enumerated.Each
experillnent was repeated at least 3 tilnes using independent cultures.
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6. Increment in mutation frequency with time
After irradiation, cells were collected and suspended in saline solution and a fraction
was immediately plated on minimal or selection plates containing 15 glL agar. After 40-
88 h, the number of swvivor colonies was determined and divided by the number of
non-irradiated colonies to determine the survivor fraction. We selected lacf mutants on
minimal medium containing 02% P-gal as the sole carbon source, as described
slssv/hgrslzrl.
III. RESI]LTS
1. Isolation of repair-defective strain
The DNA of antibiotic-selected mutants was amplified and the insertion was
determined by agarose gel electrophoresis. A DNA fragment of the expected size was
detected (date not shown).
2. Increase in mutation frequency of. fuaf
The temporal changes in the mutation frequencies of wild type and. tuaf were
determined (Figure 4-1-1 C). The survival and mutation frequencies of wild-type and
tuaf cells were not significantly different at 40 h after irradiation, (Figure 4-1-1 A, B).
The mutation frequency of both strains increased with time. There was no significant
difference in the time course.
3. Su:nrival of. E. co6cells after X'ray irradiation
The survival of wild-type, uurA, mutS, recQ, recA, and IexAS cells exponentially
decreased with increasing dose of X-rays (Figure 4-I-2A).Compared to the other cell
lines (Group I), recA and IexAS (Group II) were significantly sensitive. The survival
rates of Groups I and II were not significantly different.
4. Survival of. E. co6cells after He-ion irradiation
The survival of wild-type, uwA, mutS, recQ, recA, and IexAS cells exponentially
decreased with increasing dose of He ions (Figure 4-1-38). The survival of Group II was
lower than that of Group I, as seen in the case of X-ray irradiation. However, the
difference was less than that seen with X-ray irradiation.
5. Mutation frequency of. E. colicells after X'ray i:radiation
Cells were plated on P-gal selection medium immediately after irradiation. In the case
of X-ray irradiation, t}ne lacf mutation frequency of the wild type did not significantly
increase above the level of spontaneous mutation with the dose of 256 Gy, but increased
with increasing dose over 256 Gy (Figure 4-1-3). The laclmutation frequencies of uvrA
and recQwere similar to that seen with X-ray irradiation. T};.e lacf mutation frequency
of mutS was very high compared with that of the other types. The mutation frequencies
of recA and IexAS appeared to be independent of the radiation dose, and they both
remained very low at the level of spontaneous mutations.
6. Mutation frequency of. E. coUcells after He-ion inadiation
In the case of He-ion irradiation, the mutation frequencies of wild-type, recA, and. IexAS
cells did not increase significantly above the level of spontaneous mutations, and were
dose-independent. The value of uwA was the same as that observed with X-ray
irradiation, and the values of mutS and recQwere higher than the corresponding values
observed with X-ray irradiation. Munson and Bridges reported that the mutagenic
effect steadily decreased with increasing LETtz2l. Our results are consistent with their
findings. On the other hand, Tokarova et al. observed a clear increase in mutation
frequency after exposure of stationary cells to heavy ionst23l. This discrepancy is most
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likely due to the fact that the 2 experiments used cells in different growth phases.
TV. DISCUSSION
To observe the effect of He-rays, E. coli and its variant strains were used. They were
irradiated with X-rays or He ions and their survival and mutation frequencies were
measured.
First, I focused on DNA nicking. F-plasmid transfer is initiated by endonucleolytic
cleavage of the DNA strand. This origin-specific nicking event is modulated by the
product of trallr66'rzl. If the nick is produced near the single-strand breakpoint, it may
behave like clustered DNA damage and may mask the effects of radiation-induced
clustered DNA damage. Therefore, survival, mutation frequency, and the time course of
mutation frequency were measr.rred. No significant differences were noted between the 2
strains. Therefore, cells with an intact fuaf gene were used in subsequent experiments.
In the case of X-ray irradiation, survival of the wild-type, uurA, mutS, and recQ
strains (Group I) were higher than those of the recA and.IexAS strains (Group II) (Fig.
4'L-2A). RecA and LexA, the products of the recA and IexA genes, respectively, are
closely linked to the SOS response. Consistent with previous 1'ssulhlzs-zsl, recA and
IexAS cells were much more sensitive than the wild-type cells. The increased sensitivity
of recA or IexAS can be explained by their lack of an SOS response.
To compare the sensitivity of each strain, Do.or, which is determined as the dose
(Gy) required to reduce the surviving fraction to Lo/o, was calculated on the basis of the
survival curves (Table 4-1-1). The ratios of sensitive recA and IexAS to wild type were
3.0 and 2.9, respectively. Although uwA was a little sensitive than wild type, no
significant difference was observed in the Group I strains.
UV light irradiation induces the formation of cyclobutane pyrimidine dimers
between adjacent pyrimidinesl26,21l.IJvrA, which is the product of uwA, is one of the key
E. coli proteins involved in removing DNA damage during the process of NERt2Sl. UwA
is important for repairing pyrimidine dimers because uwA-defective strains are
sensitive to UV irradiationt2e,sol. The antitumor agent cis-diamminedichloroplatinum(ID (DDD produces DNA intrastrand, interstrand, and DNA-protein crosslinkstsrl. E.
coli cells that are uurA deftcient are more sensitive to DDP than wild-type cells,
indicating that Uvr endonuclease-mediated excision repair contributes to the repair of
DDP-induced DNA damagetaz-s+1. RecQ helicase is a key component of the RecF pathway
in E. coli for initiation of homologous recombination[35,36]. RecQ is not important for
repairing DNA defects induced by y-rays or IfV irradiation in nuclease-deficient strains
because RecA and RecBCD can regulate homologous recombinationt3Tl. On the other
hand, recQdeficient strains are sensitive to camptothecintssl. Camptothecin prevents
DNA re-ligation and therefore causes DNA damage, which results in apoptosis. Thus,
X-ray or He-ion irradiation does not appear to elicit DNA damage because there were no
differences between the wild type, uvrA, and recQ strains in my study.
The mutation frequency of. mutS was much higher than that if wild type, although
the survival of mutS was not different. The MutS protein initiates MMR and reduces
DNA replication errors in E. collssl. Therefore, mutS displays elevated spontaneous
mutation rates because of a deficiency in the postreplicative mismatch correction
process[4o]. Thus, it may be difficult to make a fair comparison between mutS and the
other strains. Given that the survival of. mutS was affected to the same extent as the
X-ray-irradiated strains, MMR requiring MutS is unusual or it may be repaired via a
different pathway. It is well known that some DNA repair systems complement the
function of other repair syste6star-aal. Precisely for this reason, the rate of DNA
mutations may be underestimated.
Group II was also more sensitive to He-ion irradiation than Group I. This
indicates that the SOS response is important to repair not only X-ray -induced damage
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but also He-ion-induced damage. The relative biological effectiveness (RBE) of He ions
relative to X-rays was calculated from Do.or, which was calculated foom Ftg. 4-I-2 (Table
4-1-1). The RBE values were approximately 3.0 and 2.9 for recA and IexA, respectively.
The value for mutSwas high (1.7), compared with that of previous studieslasl. fhsrsfsrs,
more experiments are warranted. The values for the other Group I strains were
approximately 1.3, which is almost the same as that of previous studiest4sl. It has been
reported that the RBE of 40 MeV He ions is about 1t461. The increase in RBE appears to
be due to high LET (not the radiation type). The RBE values for recA and IexAS were
less than 1. It seems like the decrease of the RBE versus LET curve at LET values
above more than 100 keV/pmt4d. This effect has been interpreted as an "overkill effect,"
where the density of ionizations within a single cell is greater than the 2 events needed
for the inactivation of that cell. This is, in effect, a wasted dose. In the cases of recA and
IexAJ in the present study, the same effect may have occurred. Of course, the value
cannot be used to calculate the dose for BNCT treatment, because the DNA repair
systems in E. coli and humans are different.
The mutation frequencies of both wild-type and rccA cells did not significantly
increase above the level of spontaneous mutations, and were independent of dose. This
suggests that the damage induced by He-ion irradiation is easy to repair or the
damaged cells did not survive or both. The difference in the sensitivities of wild-type
and Group II cells to He-ion irradiation was small compared with that of X-ray
irradiation. Thus, the contribution of the SOS response may be minimal in response to
He-ion irradiation. The SOS response is an error-prone repair systeptasJ and its
minimal contribution may explain the low mutation frequencies.
The IacI mutation foequency of the recQ strain in response to He-ion irradiation
was higher than that of X-ray irradiation. RecQ helicase is a key component of the RecF
pathway in E. coli for initiation of homologous recombinationt3s,36l. The repair system
using the RecF pathway may be important for recovery from He-ion-induced damage.
Tlne lacf mutation frequency of the mutS strain was different from that observed with
X-ray irradiation. However, the values at 0 Gy were quite different. Thus, t}:e mutS
strain needs to be further investigated.
These results are useful and fundamental to the studies of DNA repair and dose
calculation. However, various types of mutations should be examined to determine the
different types of radiation-induced DNA damage. The attempts to use streptomycin,
rifampicin, and X-gal were unsuccessful. Therefore, the accuracy of the analyzing
system should be improved or an alternative method should be used to detect significant
differences.
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Figures
Table 4-1-1 Genes, their protein products, and the associated repair mechanisms
examined in this study
gene protein repair mechanism
uwA UvrA Nucleotide excision repair
mutS MutS mismatch repair
recQ RecQ homologous recombination
recA RecA homologous recombination
and SOS response
lexA3 variant LexA SOS response
Table 4-L-2. Do.or of each strain for X-ray and He-ion irradiation and the RBE values
Wild type mutS uurA recQ recA IexAS
X'ray 552 573 456 518 181 L94
He ray 42L 353 356 4O4 217 196
RBE 1.3     1.6     1.3     1.3   0.84    0.97
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Figure 4‐1‐1.Surv市a160 and mutation frequency(D ofcells plated immediately after
X‐irradiation and counted at 40 hours after irradiation.(C)Tilne course of lnutation
frequency after X‐ray irradiation.仏,D:Wild type(solid symbols),レ′」(open symbols).
(C)Wild type(solid symbols),ヒ証6pen symbols),O Gy(■;□ 200G,(◆,◇),400 Gy
(▲,△),600 Gy(●,O).
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Figure 4-I-2. Survival of cells plated immediately after X-ray irradiation (A) and He-ion
irradiation (g). Wila type (r), mutS(z), uwA(L), recQ(t), recA(.), IexAJG).
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Figure 4-I-3. Iacf mutation frequencies after X-ray irradiation (A) and He-ion
irradiation (B). Wild type (r), mutS(t), uwA(L), rccQ(t), recA(.), IexAS (o). the
mutation frequency was measured by plating irradiated cells on P-gal selection medium
immediately after irradiation. Mutation frequencies were not plotted when the number
of mutants was less than 5 per plate because these data had large statistical errors.
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Section 2. Medium-dependent radiation sensitivity and mutagenesis with
different qualities of radiation.
I. Introduction
Ionizing radiation is used extensively for various applications, such as food sterilization
and mutational breeding to microorganisms, and medical radiography and cancer
therapy to humans. Understanding of the details of the factors/conditions that affect
radiation effects as well as their underlying mechanisms will be essential to evaluate
the effects of radiation exposure in improving the effectiveness and./or the safeness of
these applications. It has been known that the radiation sensitivity of a cell strongly
depends on its physiological state, such as its level of stress or stage of growlfutt1.
Escherichia coli is a useful model to elucidate the effect of ionizing radiation, and
the genetic basis as well as the cellular response to ionizing radiation has been
extensively investigated. It possesses several repair pathways, such as base excision
repair and homologous recombination, to cope with various types of radiation-induced
DNA damage, which are relevant to the biological consequences of ionizing radiationt2l.
E. coli has a cellular response, called the SOS response, that is induced by DNA
damaging agents[3,4], and that involves more than 40 genes related not only to DNA
repair but also to mutagenesis. The products of two of these genes, RecA and LexA,
regulate the induction of the SOS response after cells are exposed to genotoxic stress.
LexA is a repressor which binds to a motif called the SOS box located upstream of the
regulated genes. RecA is essential for homologous recombination as it binds to
single-stranded DNA, which is generated when the replication fork encounters
replication-blocking lesions or after exonucleolytic processing of double-strand breaks
(DSBs), and forms a nucleofilament to facilitate the search for a homologous sequence.
RecA also has a regulatory role: it becomes activated after binding to DNA, and in its
activated form degrades LexA. Null mutants of recA show no SOS response. Mutants of
IexAthat are resistant to degradation also show no SOS response.
Nutritional conditions directly influence the growth rate and gene expression
profiles of E. coll\-sl, and thus, nutrients are considered to affect the physiological
conditions of the ceII. The radiation sensitivity of E. colicells was found to depend on the
culture media in which they were grown. Survival was higher for cells incubated in rich
medium both pre- and post- irradiation than for cells grown in minimal medium both
pre- and post- irradiation. Interestingly, the rich medium-dependent increase of
survival is diminished when minimal medium was used either pre- or post-irradiation.
Further, addition of the antibiotic rifampicin, a transcriptional inhibitor, also reduced
the rich medium-dependent survival, indicating that de noyo RNA (and protein)
synthesis is required for the process. The idea that DNA repair plays an important role
in the rich medium-enhanced survival is supported by two lines of evidence: (f) OSg
repair was more efficient in rich medium than in minimal medium, and (2) DNA
repair-deficient mutants, such as recA, recB or IexA, did not show any medium
dependencyte-1l]. Because the deficiency of RecA or LexA completely abolished the
process, the SOS response is most likely involved in the rich medium-dependent
increase of survivaltel. The mutagenesis of .E'. colicells was also found to depend on the
growth medium. Using arginine auxotrophic mutants, Grigg demonstrated that the
reverse mutation frequency is higher when X-irradiated cells were grown in minimal
medium supplemented with rich medium than when X-irradiated cells were grown in
plain minimal mediumtl2l.
Although medium dependence of survival after X'ray exposure has been studied in
detail, the mechanism of medium-dependent mutagenesis, for instance, which gene(s)
and cellular response(s) are responsible for the process, is still largely unknown.
Further, to what extent the medium-dependent effect is affected by the ionizing density
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of a radiation, which is usually related to the linear energy transfer (LET), remains
unclear. Therefore, in this study, we used E. coli wild-type cells and E. coli recA and.
IexA mutants to determine how (1) the medium affects mutagenesis, and (2) radiation
quality affects the medium-dependent radiation effects. We found that the mutagenesis
was medium-dependent after X-irradiation and that this medium-dependent
mutagenesis was dependent on RecA and LexA. Further, we found that the
medium-dependent effects on both survival and mutation were less pronounced when
the cells were irradiated with densely ionizing, high-LET He ions. These results should
help to improve the efficiencies of radiation applications, especially for mutational
breeding.
II. Materials and methods
1. Bacterial strains
Wild-type strain CSH100, and strains JW3996-1 and DM49 were provided from t}re E.
coliGenetic Stock Center, Yale University. CSH1OorecAwas constructed by transducing
a recA::CmR allele from strain AJW807 by P1 phage. AJW807, was a kind gift from Dr.
A. J. Wolfe. CSH1001exAJ was constructed by two steps. Firstly, IamfJ::f'{s2r lvo^
JW3996-1 was transduced to DM49. Secondly, t}re IexAS allele was co-transduced with
IamB::Kan, to CSH100 by P1 transduction. The transfer of the IexAS alIele was verified
by PCR amplification and subsequent MspI (New England Biolabs, Ipswich, UK)
digestion of the hex/lIosrsltll.
2. Growth of cells
Minimal medium (containing 10.5 gll of IGHPO+, 4.5 g,lLof KHzPOa, I glL of (NH+)zSO+,
0.5 g/L of sodium citrate, 1 mM of MgSOa, 5 x lO a%o of thiamine hydrochloride and 0.2%
of glucose) (Wako Pure Chemical Industries, Ltd., Osaka, Japan) and rich medium (LB
broth Lennox (Becton, Dickinson and Company, NJ, USA) were used for growing cells.
For irradiation, cells were prepared according to the protocol of Maezawah4l. In brief,
Iogarithmic cells were prepared by diluting the overnight culture 5O-fold (for minimal
medium grown cells) or l-OO-fold (for rich-medium grown cells) by respective homologous
medium and by subsequent incubation for several hr at 37 oC to reach a cell density of
approximately 4 X 108 cells per mI. Logarithmic cells were washed and resuspended in
saline (O.rfU NaCD (Wako Pure Chemical Industries, Ltd., Osaka, Japan), and were
retained on a nitrocellulose membrane (Vfn-Uittipore, GSWP01300, EMD Millipore
Corporation, MA, USA). These membranes were placed on saline solid plates for
irradiation.
3. X-ray irradiation
X-rays were irradiated using Soft X-ray generator with a tungsten target (SOFTEX
M-I-50WE, SOFTEX Co., Ltd., Kanagawa, Japan) at room temperature. The peak
electrical voltage was set at 150 kVp and the current was set at 6 mA. The dose rate was
27,9 Gylmin, which was determined by Fricke dosimeter.
4. He-ion irradiation
Cells were exposed to He ions, which were generated by the AVF cyclotron at Takasaki
Ion Accelerators for Advanced Radiation Application, at room temperature. The energy
of He ions (fOUeD was reduced by placing a Ni filter with 300 pm thickness in front of
the sample. The average LET of the sample was estimated by ELOSS code, a modified
OSCAR codehsl, and was 89 keV/pm. The particle fluence was measured using CR39
plastic dosimeter (UanZf-aS TD-1, Fukuvi Chemical Industry Inc., Fukui, Japan) to
calculate the absorbed dose. The dose rate was 8-10 Gy/sec.
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5. Measurement of survival and mutant frequency plated immediately after irradiation
After irradiation, cells were collected and suspended in saline solution and a fraction
immediately plated to minimal, rich or selection plates (containing 15 gll agar)(Bacto-agar, Becton, Dickinson and Company, NJ, USA). The number of survived
colonies was counted and divided by the number of unirradiated colonies to determine
the survived fraction. Iacf mutants were selected on a minimal medium containing
P-gal (O.ZN) (Wat<o Pure Chemical Industries, Ltd., Osaka, Japan) as a sole carbon
source, following the procedure as described elsewhsrstrel. The mutant frequency was
calculated by dividing the number of laclmutants on P-Gal medium with the number of
survived colonies on glucose minimal medium. Each experiment was repeated at least
three times foom independent cultures.
6. Measurement of medium-dependent sensitivity/mutagenesis of irradiated cells
The cells were pre-cultured in rich medium and were irradiated as describe above. After
irradiation, cells were cultured in solution of either minimal or rich medium for 2ltr, to
assay medium-dependent sensitivity/mutagenesis. After incubation, cells were washed
with saline solution and plated on minimal, rich or selection plates to assess the effect of
growth medium on the survival or mutation frequency. Each experiment was repeated
at least three times from independent cultures.
III. Results
1. Snrvival of E. colicelfs plated immediately after irradiation
The survival of wild-type, recA, and IexA after cells decreased exponentially with
increasing dose of both X-rays (Figure 4-2-lA) and He ions (Figure 4-2-LB). The survival
rates were not significantly different between the two types of radiation, except that, for
wild-type cells, there was a medium-dependent increase of survival after X-irradiation
but not after He ion radiation. Consistent with previous 1'ssuhslrz-r0l, tlne recA and IexAS
cell lines were much more sensitive than the wild type to both types of radiation. The
increased sensitivity of recA or IexAS could be explained by their lack of an SOS
response.
2. Mutation frequency of. E. coU cells plated immediately after irradiation
Cells were grown in rich medium pre-irradiation and plated on P-gal selection medium
immediately after irradiation. In the case of X-irradiation, the lacf mvtation frequency
of the wild type did not significantly increase above the level of spontaneous mutation
with the dose of 256 Gy, but increased with increasing dose over 256 Gy (Figure 4-2-2).
The mutation frequencies of recA and IexAS appeared to be independent of dose, and
they both remained very low at the level of spontaneous mutations, confirming that the
SOS response is required for low-LET radiation mutagenesist2o'2ll. Induced mutations
were also hardly observed when rccA and IexAS cells were grown in minimal medium
prior to irradiation (data not shown). In the case of He-irradiation, the mutation
frequencies of all wild-type, recA, and IexAS cells did not increase significantly above
the level of spontaneous mutation, and were independent of dose and the type of growth
medium. Our results showing that high-LET radiation induces less mutations per dose
than Iow-LET radiation are consistent with previous observationsl22/;l. However, a clear
increase of mutation frequency after exposing E. coli cells to several kinds of heavy ions
have been observedlzz'z+-zz). Qnspossible explanation for this discrepancy could be due to
the fact that those experiments with increased mutation frequency exposed cells of
stationary phase to ion particles.
3. Survival of cells incubated for 2 br in tiquid rich medium post-inadiation
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To find out the duration that cells show medium-dependent radioresistance
post-irradiation, we looked at the survival of cells incubated in liquid rich medium after
irradation. Those cells were incubated in liquid rich medium pre-irradiation. The
numbers of unirradiated wild-type, recA, and IexAS cells increased approximately
lO-fold in liquid rich medium. The growth rate of each strain was reduced with
increasing dose of radiation, probably due to both cell death and growth arrest after
irradiation. Wild-type cells that were incubated for 2 hr post-irradiation of X-rays
showed no enhancement of medium-dependent survival (Figure 4-2-3A). As expected, no
enhancement was observed in either X-irradiated recAor IexAS cells (Figure 4-2.38),
and in wild-type cells after He-irradiation (Figure 4-2-3C).
4. Mutation frequency of cells incubated for 2 hr in liquid medium post'irradiation
Cells were incubated in liquid rich medium pre-irradiation and in either liquid minimal
or rich medium for 2}r post-irradiation, and then plated on solid P-gal medium to
detect IacI mttants. The mutation frequencies of unirradiated wild-type cells (Figure
4-2-4A) and recA and. IexAS cells did not change with or without the 2hr-incubation (Fig.
4-2-2,Fig.4-2-4Aand Figure 4-2-48).Interestingly, for X-irradiated wild-type cells, the
mutation frequencies plated after 2 hr post-irradiation incubation in both liquid rich
and minimal medium were higher than the mutation frequencies in cells that were
plated immediately after irradiation (nig. +-Z-Z and Fig. 4-2-4A). More surprisingly, the
mutation frequency after 2 hr post-irradiation incubation in liquid rich medium was
significantly higher than that after 2 hr post-irradiation incubation in liquid minimal
medium (Fig. a-2-al\). This rich-medium-dependent increase of mutation frequency was
not found in either recA cells or IexAS cells, as the mutation frequency stayed low at the
level of spontaneous mutation in each cells (Fig. 4-2-48). When wild-type cells were
irradiated with He ions, there was no clear increase of the mutation frequency either
with or without post-irradiation incubation (Fig. 2 and Figure 4-2-4C).
IV. Discussion
Using E. coli cells, we found that X-ray mutagenesis was significantly enhanced in rich
medium and that the process was dependent on RecA and LexA. We did not observe the
rich-medium-dependent enhancements of survival and mutation frequency with
densely ionizing, high-LET radiation. Our results demonstrate that medium-dependent
survival and mutagenesis are differently affected by exposures to different types of
ionizing radiation.
Growth medium-dependent effects of X-i:radiated E. colicells
Our results confirm previous reports that E. coli cells have enhanced radiation
resistance when grown on rich medium (LB) and that recA and IexAS cells do not share
this medium-dependent sensitivity (Fig 4-2-7)lel. These results strongly indicate that
SOS response is involved in radiation resistance. It is noteworthy that the
medium-dependent increase in survival was observed only when cells were incubated in
rich medium both pre- and post-irradiation, and not when cells were grown in minimal
medium either pre' or post-irradiation (data not shown). These results suggest that a
specific physiological state induced by the rich medium is required prior and subsequent
to irradiation to induce sufficient SOS response to enhance survival.
The E. coli strains used in this study have an F' plasmid, which harbors t}:e pro
gene that is required for growth only in minimal medium. Thus, the
rich-medium-dependent increase of survival may be merely the result of rescuing cells
that had lost the F'plasmid. However, this explanation is ruled out by the finding that
the survival rates of wild-type cells, which were incubated in liquid rich medium for 2hr
post-irradiation, on solid rich medium and on solid minimal medium did not differ (Fig.
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4-2-3N. This indicates that the F'plasmid is not lost in rich medium post-irradiation.
Several lines of evidence suggests that the rich medium is required immediately but
only for 2br or less after irradiation to enhance survival: (1) a rich medium-dependent
increase of survival was observed when cells were plated immediately on solid rich
medium after irradiation (Fig. a-2-U), (2) such an increase was absent after cells were
incubated in either rich or minimal medium for 2hr post-irradiation (Fig. 4-2-3A, data
not shown). Because the survivals of recA and IexAS cells with post-irradiation
incubation did not show any medium dependence (Fig. 4-2-38), the efficiency with
which DNA damage is repaired during the 2-hr incubation after X-irradiation is most
likely enhanced by the SOS repair. The SOS response is at least partly functional in the
minimal medium, since wild-type cells show higher survival than do recA and IexAS(Fig. 
 
-2-1). We assume that the'extra'activity specifically expressed in rich medium is
responsible for the medium-dependent increase of survival.
Interestingly, when X-irradiated wild-type cells were incubated in liquid medium
for 2 hr after irradiation, the mutation frequency was increased compared to that of
cells without post-irradiation incubation (Fie. a-2-2 and Fig. 4-2-4A). The increase of
mutation frequency of X-irradiated wild-type cells was significantly Iager in cells
incubated in liquid rich medium than in cells incubated in liquid minimal medium,
indicating that the incubation of X-irradiated cells in rich medium strongly enhances
mutagenesis (Fig. 4-2-2 and Fig. a-2-a$. This medium-dependent enhancement of
mutation frequency did not occur in recAcells or IexAScelIs (FiS. a-2-2 and Fig. 4-2-48),
indicating that the SOS response is involved in the mutagenic process and that the
'extra' activity of SOS response is likely responsible for the significant increase of
mutation frequencies in rich medium. The mutations induced by the SOS response may
have occurred at two different times: (1) during t}re 2 hr-incubation post-irradiation
before plating on P'gal minimal medium, or (2) after plating on P-gal minimal medium
by the process called'adaptive mutationt28l. It is unclear at which time the mutants
arose. In either case, the 2-hr incubation post-irradiation is sufficient to increase the
frequency of mutations in E. coli.
Growth medium-dependent effects of He-i:radiated. E. colicells
No medium-dependent increase of survival was found for He-irradiated wlld-type, recA
or IexAS cells (Fig. 4-2-IB). The medium-dependent resistance and mutagenesis after
X-irradiation lead us to suggest that the 'extra' SOS response is inactive after
He-irradiation. However, Kozubek et al., using a sulAllacZfusion gene, where sulAis an
SOS-inducible gene, demonstrated that the SOS response is also efficiently induced by
densely-ionizing heavy i6nstzol. The most likely explanation for this apparent
discrepancy is that although the SOS response is fully induced in rich medium, the
induced oextra'proteins cannot cope with some of the complex DSBs that were generated
by He-irradiation. Exposure to high-LET radiation is known to result in spatial
clustering of DNA damage, which, in turn, leads to reduced repair efficiencytao,atl. f2ff4
et aI. have shown that a complex DSB with DNA damage confined to the proximity of
the break ends was induced by densely-ionizing 125I decaytsz'esl, and was difficult to
repailtsal.
We also found that the mutation frequencies of wild-type cells irradiated with He
ions did not increase significantly above the level of spontaneous mutation frequency(Fig. a-2-D and that the medium-dependent mutagenesis did not occur (Fis. +'Z-Z and
Fig. a-2-aC). Since translesion synthesis (TLS) induced as part of the SOS response is
mainly responsible for mutagenesis after ionizing radiation exposure[2,20], we suggest
that at least one of the following possibilities is responsible for the absence of
medium-dependent increase of mutation frequency, as well as the low mutation
frequencies of cells immediately plated after He-irradiation: (f) tne polymerases for TLS
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can replicate over He-damaged DNA, and do so in an error-free manner, (2) the
polymerases for TLS cannot replicate over damaged DNA generated by He-irradiation,
and thus the replication is blocked, or (3) there is only a small amount of DNA damage
on double-stranded regions and that most of the DNA damage is gathered around
complex DSBs. In the last case, we assume that complex DSBs have low mutagenicity if
repaired, as exonucleases can remove damaged sites during homologous
recombination135,36l.
V. Conclusions
We found that, in addition to medium-dependent sensitivity, there is
medium-dependent mutagenesis in -E coli ceIIs after ionizing radiation exposure, which
requires an SOS response. Our results suggest that the incubation in rich medium
before and after irradiation sets the physiological condition of a cell that results in
medium-dependent effects. Thus, the physiological state of the cell plays an important
role in determining the mutagenic consequences of X-irradiation. Furthermore, our
finding that the medium-dependent effects are absent after exposure to high-LET
radiation indicates that the higher level of clustering of DNA lesions is, at least partly,
refractory to the SOS response. These results imply that both the physiological state of
the cell and the radiation quality are important in determining the radiation effect to
microorganisms, which gives valuable insights in radiation breeding, food sterilization
and medical aplication.
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Figure 4-2-I. Survival of cells plated immediately after X-irradiation (A) and
He-irradiation (B). Cells were grown pre- and post-irradiation in minimal (solid
symbol) or rich (open symboD medium. Wild type (r, r), recA(L, d,), IexAS(c, o). Each
data point represents the mean of at least three independent experiments, and the
error bar denotes standard error. A data point without an error bar indicates that the
error bar was smaller than the svmbol.
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Figure 4-2-2. Iacf mutant frequencies after X-irradiation (solid symbols) and
He-irradiation (open symbols). Wild type (r, r), recA(L, L), IexAS (., o). Cells were
grown in liquid rich medium pre-irradiation. The mutant frequency was measured by
plating irradiated cells on P-gal selection medium immediately after irradiation. Each
data point represents the mean of at least three independent experiments, and the error
bar denotes standard error. A data point without an error bar indicates that the error
bar was smaller than the symbol. We did not plot mutant frequencies when the number
of mutants was less than 5 per plate because these data had very large statistical errors.
The data points that are not shown are: the mutant frequencies of X-irradiated recA
(aSa Gy), He-irradiated recA (gOO Gy), X-irradiated IexAS (aS+ Gy), and He-irradiated
lexA? eo} G').
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Figure.4-2- 3 Survival of cells incubated in liquid rich medium for 2 hr post-irradiation.
Cells were grown in liquid rich medium pre-irradiation, and subsequently plated on
solid minimal (solid symbols) or rich (open symbols) medium after post-irradiation
incubation. G) Wla-type cells incubated for 2 hr post X-irradiation (r, n), (B) recA (t,
a) and IexAS (., o) cells incubated for 2 hr post X-irradiation, (C) wild-type cells
incubated for 2 hr post He-irradiation (r, n). Each data point represents the mean of at
Ieast three independent experiments, and the error bar denotes standard error. A data
point without an error bar indicates that the error bar was smaller than the symbol.
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Figure 4-2-4. Iacf mtttant frequencies of cells incubated for 2 hr post-irradiation in
liquid minimal (solid symbols) or rich (open symbols) medium. G) Wita-type cells
irradiated with X-rays (r, n), (B) recA (a) and IexAS (o) irradiated with X-rays, (C)
Wild-type cells irradiated with He ions (r, r). Each data point represents the mean of at
least three independent experiments, and the error bar denotes standard error. A data
point without an error bar indicates that the error bar was smaller than the symbol.
Due to low mutant frequencies with very large statistical errors, following data are not
plotted: recA(256 and 384 Gy), IexAS (250 and 384 Gy), wild type inadiated with He
ions and incubated for 2lnr post-irradiation in liquid minimal medium (6OOCy)
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Chapter 5. General overview and Summaries
This paper attempts to develop the novel cancer therapyi Photodynamic therapy (PDT)
and Boron Neutron Capture Therapy (BNCT), by using Drug Delivery System. PDT and
BNCT is one of the less invasive cancer treatments. They use quantum beam to excite
the specific drug and the active oxygen or radiation produced by the excited drug make
selective cytotoxicity.
The first, I determined the accumulation ability of HVJ-E using PDT (2-f). The
accumulation with IIVJ-E was 3 times higher than that with the photosensitizer alone
and 20 times higher than that with ordinary method. In the study, the take-up ability
was significantly different with cell line. In the result of detailed investigation, some
subclones have different photosensitizer uptake ability and PDT sensitivity than the
others, though they have same DNA and were differentiated from same cell (Z'Z).lt
shows that a small fraction of tolerant cells may actively grow and predominate after
PDI even though most of the non-tolerant cells in the original tumor tissue were
selectively killed by the repeated treatment in clinical therapy. To effective treatment,
enough cytotoxicity to kill the small function of cells is needed.
From the result of section 2-1, more than l- x l-00 n/seclcmz of thermal neutron flux
is thus needed for BNCT when HVJ-E is used. OKTAVIAN facility generates 14 MeV
neutrons via D-T reaction. The produced 14 MeV neutrons have to be moderated to
thermal neutron. And the stably produced neutron source intensity is 
- 
1 x l-Oto n/sec at
present. I carried out simulation calculations to design a thermal neutron field (3-1).
With the result, the neutron flux at inadiation field was about 1.6 x 10-a n/cm2lsource
neutron using 20cm thickness of polyethylene moderator and there is possibility that
the anti-tumor effect of BNCT can be observed using the novel boron agent in in-vitro
experiment. After that, a thermal column was built in the heavy inadiation room of
OKTAVIAN, and irradiation experiments were performed (a-Z). tne thermal neutron
flux at the sample area achieved 1.6 x 106 n/cm2ls, and the dose of BNCT was 3.4 Gy-eq
for 2 hour irradiation. With the irradiation more than 50% of anti-tumor effect was
observed in in-vitro experiment. However the anti-tumor effect was not observed in
in-vivo experiment. The experimental method need to be improved.
In Chapter 3, equivalent dose was calculated to evaluate the BNCT effect, and the
value was compared with those from other studies on the same cell line. Although the
RBE value of each nuclear reaction was determined in the previous study, some points
remain unclear. Tb accurately calculate the dose and administer treatment with the
least side effects, the radiological consequences need to be precisely assessed. Then I
studied the mechanism of cellular disorder comparing photon-ray and cr-ray, which is
generated in BNCT reaction (+-f). Ttre relative biological effectiveness (RBE) of He ions
relative to X-rays was calculated from Do.or, which was calculated from Fig.4-1,'2 (Table
4-1-1). The RBE values were approximately 1.3 for Group I (wild-type, recQ and uwA)
and 3.0 for recA and, IexA. The medium-dependent survival and mutagenesis were also
observed (a-Z). ttre SOS reaction was needed for medium dependency. From the result,
it could be argued that cellular environment of tumor is considerable to effective
treatment.
The summaries of each section were described below.
Section 2-1.
Photodynamic therapy (PDT) is a photochemical modality approved for cancer
treatment. The accumulation of photosensitizers in cancer cells is necess€rry to enhance
the therapeutic benefits of PDT; however, photosensitizers have a low uptake efficiency.
To overcome this limitation, a drug delivery system (lns), such as Hemagglutinating
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virus of Japan envelope (HVJ-E) vector, is required. In this study, the combination of
PDT and HVJ-E was investigated for enhancing the efficacy of PDT. The
photosensitizers that were evaluated included 5-aminolaevulinic acid (5-ALA),
protoporphyrin IX (PPID, and HVJ-PPIX. The uptake of the photosensitizers as
increased twenty-fold with the addition of HVJ-E. The cytotoxicity of conventional
5-ALA was enhanced by the addition of IfVJ-E vector. In conclusion, HVJ-E vector
improved the uptake of photosensitizers and the PDT effect.
Section 2-2
Photodynamic therapy (PDT) involves the administration of a photosensitizer, followed
by local illumination of a tumor with a laser (of the appropriate wavetength) to activate
a specific drug. However, the cells in a tumor tissue are heterogeneous, in terms of their
morphologies and differentiation statuses, even if the tumor consists of progeny
developed from a single neoplastic cell. It is not known how tumor cell heterogeneity
affects their sensitivity to PDT. Here, I demonstrate that a single tumor cell has the
potential to produce a progeny that is heterogeneous in terms of morphology, VEGF
secretion, and PDT sensitivity, irrespective of intracellular photosensitizer amount.
Understanding tumor cell heterogeneity for clinical applications of PDT will help in the
design of new interventions and potentially improve long-term sr-rvival of PDT treated
patients.
Section 3-1
BNCT is inefficient because nuclear reactor is used for neutron source. To improve
BNCT, accelerator-based BNCT is needed. Though I tried to build the set up for BNCT
experiment using culture cell or mice in accelerator facilities, it was difficult because of
the weakness of accelerator-based neutron source. The effect of BNCT calculated from
the product of boron concentration and thermal neutron flux. If the 1oB concentration
could be increased, even a little weak neutron source would be available. These days
various kinds of boron agents were developed and the concentration in tumor cells is
approximately 1-0 times higher than that of a conventional way. In this study, I made an
accelerator-based BNCT set up for novel boron agents using simulation calculations. In
the result the neutron flux at irradiation field was about 1.6x10-a [n/cm2lsource
neutronl and there is possibility that the anti-tumor effect of BNCT can be observed
using the novel boron agent in in-vitro experiment. The series study showed the
potential of the accelerator-based BNCT.
Section 3-2
BNCT (Boron Neutron Capture Therapy) is one of the effective treatments for cancers.
However, BNCT is inefficient at present because nuclear reactor is required as a
neutron source. Various studies started so far to realtze accelerator-based neutron
source. However, such kinds of accelerators are not yet realized because ofweakness of
accelerator-based neutron source. Recently, several studies proposed new efficient
agents which can accumulate boron in tumor approximately 1-0 times higher than before.
Even a little weak neutron source would be thus available with novel boron agents. In
this study, I designed and constructed a thermal neutron field with a D-T neutron
source to carry out basic BNCT experiments with cultured cell or small animals with
help of new boron agents. In the experiment, the BNCT dose was 5.0 Gy-eq for 2 hour
irradiation and fast neutron and gamma ray doses were suppressed to be 0.31 Gy-eq
and 0.023 Gy, respectively. It was confirmed that the anti-tumor effect of BNCT could be
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observed in in vivo experiment at the present neutron filed. And it was found that it
would be possible to realize a D-T-based BNCT, if the source neutron intensity would be
larger than 
-LOtz n/s.
Section 3-3
In the previous study, the effect of BNCT was not observed using small animals. The
poor result was thought to be due to lack of affinity of LLC. The up-take abilities of each
cell line were need to be compared using BSH. I compared the up-take abilities of four
cell lines, and 816 cells have highest. The value was about twofold greater than LLC.
The set-up was also improved, because deuterium water came to be used. The
predominance of deuterium water was indicated in previous study. As the result, the
thermal neutron flux at the sample area was increased to 8.9x1-06 n/cm2lsec. In the
study, I could suggest a possible beneficial effect of in-vitro BNCT experiment.
Section 4-1
There are many types of radiation and each has its own mechanism of action. Especially,
the effects of high-linear energ'y transfer (LET) radiation are different from those of
X-rays or y-rays. High-LET radiation tends to inflict great damage on DNA via direct
effects and the damage is easily clustered. To determine the difference, I compared the
effects of He-ray and x-ray using Wild-type Escherichia coli (8. coD and its mutants.
Though typical different damage was not observed, some new knowledge concerning
DNA damages induced by high-LET radiation was obtained. It would Iead to the
discovery of the effect of high-LET radiation.
Section 4-2
The sensitivity to radiation depends on the physiological state of cells. For example, in
E. coli, the survival of cells after irradiation is affected by the growth medium. In the
present stud5r, I analyzed E. coli cells to determine (f) tfre level of medium-dependent
mutagenesis, and 0) the effects of the quality of radiation on medium-dependent
survival and mutagenesis. Cells were exposed to low-linear energ'y transfer (LET)
X-rays and then grown on rich and minimal media. I found that both survival and
mutation frequencies were higher in the cells grown on rich medium. The increases of
survival and mutation frequency were both strongly dependent on the function of RecA
or LexA, suggesting that SOS repair is responsible for the medium-dependent
sensitivity and mutagenesis. In contrast, high-LET He ions failed to demonstrate
medium-dependent radiation resistance, and did not induce mutations. I suggest that
the damage from He ions is too severe to stimulate survival or mutagenesis on rich
medium and that SOS repair does not fully function after He ion-irradiation.
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